

Approved



Swaziland

Country Operational Plan

FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		935,144		935,144
HHS/CDC	487,500	19,734,769		20,222,269
HHS/HRSA		25,000		25,000
PC		1,112,762		1,112,762
State		115,000		115,000
State/AF		500,000		500,000
USAID		13,989,825	6,900,000	20,889,825
Total	487,500	36,412,500	6,900,000	43,800,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency								On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	AllOther		
CIRC		7,914					2,676,215		0	2,684,129
HBHC		87,914	926,064				2,102,414		0	3,116,392
HKID	0				72,240	0	3,725,734		0	3,797,974
HLAB		3,957	179,143				100,000		0	283,100
HMBL			100,000						0	100,000
HTXD							600,000		0	600,000
HTXS	0	514,702	2,809,297			250,000	2,568,415		0	6,142,414
HVAB	0	3,957			3,000	0	51,413		0	58,370
HVCT			1,981,983				467,219		0	2,449,202
HVMS	115,000	63,914	903,674		22,300		190,969		0	1,295,857
HVOP	0	30,000			1,015,222	0	1,498,447		0	2,543,669
HVSI	0	0	8,674,469				446,689		0	9,121,158
HVTB		137,914	2,004,567			200,000	1,704,088		0	4,046,569

Approved



MTCT		73,000	1,285,118				2,532,142		0	3,890,260
OHSS	0	11,872	139,465	25,000			480,053		0	656,390
PDCS		0	788,346				870,239		0	1,658,585
PDTX		0	430,143			50,000	875,788		0	1,355,931
	115,000	935,144	20,222,269	25,000	1,112,762	500,000	20,889,825	0	0	43,800,000



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	3,072,869	0
HKID	3,665,769	0
HVTB	3,863,581	0
PDCS	1,636,924	0
Total Technical Area Planned Funding:	12,239,143	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	258,223	0
HVSI	8,967,004	0
OHSS	380,193	0
Total Technical Area Planned Funding:	9,605,420	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	2,617,458	0
HMBL	100,000	0
HVAB	3,000	0
HVCT	2,399,648	0

Approved



HVOP	1,457,000	0
MTCT	3,780,089	0
Total Technical Area Planned Funding:	10,357,195	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	600,000	0
HTXS	5,577,089	0
PDTX	1,228,557	0
Total Technical Area Planned Funding:	7,405,646	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	499	612
	By program area/support type: HTC Direct Service Delivery (DSD)	241	258
	By program area/support type: HTC Technical Assistance-only (TA)	140	140
	By program area/support type: Treatment Direct Service Delivery (DSD)	64	64
	By program area/support type: Treatment Technical Assistance-only (TA)	70	80
	By program area/support type: Care and Support Direct Service Delivery (DSD)	64	64
	By program area/support type: Care and Support Technical Assistance-only (TA)	70	80
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	31	31
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	113	113



	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	1
	By program area/support type: PMTCT Technical Assistance-only (TA)	143	143
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	64	64
	By program area/support type: TB/HIV Technical Assistance-only (TA)	70	80
	By program area/support type: VMMC Direct Service Delivery (DSD)	20	20
	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	334	447
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	30	0
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	10	17
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
	By program area/support	168	170



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	0	0
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	50	50
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
	By program area/support type: Lab Direct Service Delivery (DSD)	29	29
	By program area/support type: Lab Technical Assistance-only (TA)	101	121
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	86 %	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	124	138
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	145	145
	By site support type: Direct Service Delivery (DSD):	1	1



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	123	137
	Sum of Numerator Support Type disaggregates	124	138
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	144	144
	Sum of Denominator Support Type disaggregates	145	145
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %	
	Number of pregnant women	20	11



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	20	11
	By: Known positives at entry	17	11
	By: Number of new positives identified	3	0
	Sum of Positives Status disaggregates	20	11
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NA	PMTCT_STAT_NA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (Neither)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
	Number of new ANC and L&D clients	0	0
	By: Known positives at entry	0	0
	By: Number of new positives identified	0	0
	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	98 %	



	their results) (NGI)		
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,805	27,882
	Number of new ANC and L&D clients	28,508	28,335
	By: Known positives at entry	5,536	5,591
	By: Number of new positives identified	4,835	4,927
	Sum of Positives Status disaggregates	10,371	10,518
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	98 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,785	27,860
	Number of new ANC and L&D clients	28,488	28,313
	By: Known positives at entry	5,519	5,573
	By: Number of new positives identified	4,832	4,923
	Sum of Positives Status disaggregates	10,351	10,496
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS		



	countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator: 15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	100 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	20	11
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20	11
	Life-long ART (including Option B+)	20	11
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5	0
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	0
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	20	11
	Sum of New and Current disaggregates	20	0
PMTCT_ARV_NA	PMTCT_ARV_NA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (Neither)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	0
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	0
	Life-long ART (including Option B+)	0	0
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0
	Maternal triple ARV prophylaxis (provided with	0	0



	the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen disaggregates	0	0
	Sum of New and Current disaggregates	0	0
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,959	9,473
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,371	10,518
	Life-long ART (including Option B+)	5,410	9,473



	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,801	6,783
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,609	2,690
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	4,503	0
	Single-dose nevirapine (with or without tail)	46	0
	Sum of Regimen disaggregates	9,959	9,473
	Sum of New and Current disaggregates	5,410	9,473
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission	9,939	9,451



	(MTCT) during pregnancy and delivery		
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,351	10,496
	Life-long ART (including Option B+)	5,390	9,451
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,796	6,776
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,594	2,675
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	4,503	0
	Single-dose nevirapine (with or without tail)	46	0
	Sum of Regimen Type disaggregates	9,939	9,451
	Sum of New and Current disaggregates	5,390	9,451
BS_COLL	Number of whole blood collections each year by the NBTs network	13,400	
	By: Number of whole blood	13,400	



	donations screened for HIV in an NBTS network laboratory		
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	120	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	14,300	13,464
	By Age: <1	2,000	
	By Age: 1-9	0	0
	By Age: 10-14	8,000	
	By Age: 15-19	2,520	
	By Age: 20-24	1,090	
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	0
	Sum of age disaggregates	14,300	790
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	140	133
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,201	11,600
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for	966	1,566



	HIV at site		
	By circumcision technique: Surgical VMMC	12,060	13,060
	By circumcision technique: Device-based VMMC	2,240	2,240
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,060	12,799
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	240	261
VMMC_CIRC_NA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	0	0
	By Age: 15-19	0	0
	By Age: 20-24	0	0
	By Age: 25-49	0	0
	By Age: 50+	0	0
	Sum of Age disaggregates	0	0
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
By HIV status: Number of	0	0	



	HIV-negative clients (tested HIV negative at VMMC program)		
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	0	0
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	14,300	15,300
	By Age: <1	2,000	2,000
	By Age: 1-9	0	0
	By Age: 10-14	8,000	8,400
	By Age: 15-19	2,520	2,920
	By Age: 20-24	1,090	1,190
	By Age: 25-49	690	790



	By Age: 50+	0	0
	Sum of Age disaggregates	14,300	15,300
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	140	133
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,201	11,601
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	966	1,566
	By circumcision technique: Surgical VMMC	12,060	13,060
	By circumcision technique: Device-based VMMC	2,240	2,240
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,060	12,800
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	240	500
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	0



	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	0	0
	By Age: 15-19	0	0
	By Age: 20-24	0	0
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	0
	Sum of Age disaggregations	0	0
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	0
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	0
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
	By circumcision technique: Surgical VMMC	0	0
	By circumcision technique: Device-based VMMC	0	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	0
	By follow-up status: Number of surgically circumcised clients who did NOT return	0	0



	for follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	30 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	110,108	62,520
	Total number of people in the target population	362,138	177,563
	Age/sex: 10-14 Male	12,663	
	Age/sex: 15-19 Male	20,274	
	Age/sex: 20-24 Male	10,201	
	Age/sex: 25-49 Male	5,414	
	Age/sex: 50+ Male	778	
	Age/sex: 10-14 Female	15,378	
	Age/sex: 15-19 Female	24,418	
	Age/sex: 20-24 Female	11,995	
	Age/sex: 25-49 Female	7,596	
	Age/sex: 50+ Female	1,391	
	Sum of Age/Sex disaggregates	110,108	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum	12 %	



	components during the reporting period (TA-only)		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,100	0
	Total number of people in the target population	68,488	0
	Age/sex: 10-14 Male	0	0
	Age/sex: 15-19 Male	1,215	0
	Age/sex: 20-24 Male	1,215	0
	Age/sex: 25-49 Male	1,620	0
	Age/sex: 50+ Male	0	0
	Age/sex: 10-14 Female	0	0
	Age/sex: 15-19 Female	1,215	0
	Age/sex: 20-24 Female	1,215	0
	Age/sex: 25-49 Female	1,620	0
	Age/sex: 50+ Female	0	0
	Sum of Age/Sex disaggregates	8,100	0
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that	1,032	378



	are based on evidence and/or meet the minimum standards required		
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	732	243
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men	300	135



	<p>who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		
	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	0
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key</p>		



	population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW)	0	0



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	0	0



	minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment		



	area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	153,546	164,953
	By Test Result: Negative	131,821	143,167
	By Test Result: Positive	21,725	21,786
	Sum of Test Result disaggregates	153,546	164,953
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex:		



	Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex:		



	Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,307	27,931
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	48,818	51,471
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16,233	12,487
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	71,188	73,064
	Sum of Aggregated Age/Sex <15	33,540	40,418
	Sum of Aggregated Age/Sex 15+	120,006	124,535
	Sum of Aggregated Age/Sex disaggregates	153,546	164,953
	Service Delivery Point by Result: Antenatal Clinic - All results		



	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All		



	results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		



	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) –		



	Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	0
	By Test Result: Negative	0	0
	By Test Result: Positive	0	0
	Sum of Test Result	0	0



	disaggregates		
	Age/sex: <1 Male	0	0
	Age/sex: 1-4 Male	0	0
	Age/sex: 5-9 Male	0	0
	Age/sex: 10-14 Male	0	0
	Age/sex: 15-19 Male	0	0
	Age/sex: 20-24 Male	0	0
	Age/sex: 25-49 Male	0	0
	Age/sex: 50+ Male	0	0
	Age/sex: <1 Female	0	0
	Age/sex: 1-4 Female	0	0
	Age/sex: 5-9 Female	0	0
	Age/sex: 10-14 Female	0	0
	Age/sex: 15-19 Female	0	0
	Age/sex: 20-24 Female	0	0
	Age/sex: 25-49 Female	0	0
	Age/sex: 50+ Female	0	0
	Sum of Age/Sex disaggregates	0	0
	Aggregated Age/sex: <15 Male	0	0
	Aggregated Age/sex: 15+ Male	0	0
	Aggregated Age/sex: <15 Female	0	0
	Aggregated Age/sex: 15+ Female	0	0
	Sum of Aggregated Age/Sex <15	0	0
	Sum of Aggregated Age/Sex 15+	0	0
	Sum of Aggregated Age/Sex disaggregates	0	0



HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	251,334	275,477
	By Test Result: Negative	211,509	234,028
	By Test Result: Positive	39,825	41,449
	Sum of Test Result disaggregates	251,334	275,477
	Age/sex: <1 Male	1,821	2,030
	Age/sex: 1-4 Male	7,290	8,894
	Age/sex: 5-9 Male	4,481	4,841
	Age/sex: 10-14 Male	8,884	18,008
	Age/sex: 15-19 Male	8,942	3,908
	Age/sex: 20-24 Male	11,467	15,109
	Age/sex: 25-49 Male	38,949	44,958
	Age/sex: 50+ Male	8,253	8,740
	Age/sex: <1 Female	1,875	2,097
	Age/sex: 1-4 Female	7,533	7,473
	Age/sex: 5-9 Female	4,543	4,892
	Age/sex: 10-14 Female	9,276	5,931
	Age/sex: 15-19 Female	22,293	22,986
	Age/sex: 20-24 Female	35,137	39,044
	Age/sex: 25-49 Female	67,222	72,017
	Age/sex: 50+ Female	13,368	14,549
	Sum of Age/Sex disaggregates	251,334	275,477
	Aggregated Age/sex: <15 Male	22,477	33,773
	Aggregated Age/sex: 15+ Male	67,611	72,717
	Aggregated Age/sex: <15 Female	23,226	20,393



	Aggregated Age/sex: 15+ Female	138,020	148,594
	Sum of Aggregated Age/Sex <15	45,703	54,166
	Sum of Aggregated Age/Sex 15+	205,631	221,311
	Sum of Aggregated Age/Sex disaggregates	251,334	275,477
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	97,788	110,524
	By Test Result: Negative	79,688	90,861
	By Test Result: Positive	18,100	19,663
	Sum of Test Result disaggregates	97,788	110,524
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex:		



	Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex:		



	Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,168	5,842
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,795	21,244
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,994	7,907
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	66,831	75,531
	Sum of Aggregated Age/Sex <15	12,162	13,749
	Sum of Aggregated Age/Sex 15+	85,626	96,775
	Sum of Aggregated Age/Sex disaggregates	97,788	110,524
	Service Delivery Point by Result: Antenatal Clinic - All results		



	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All		



	results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		



	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		



	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
GEND_GBV_DSD	Number of people receiving post-GBV care	0	0
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		



	Age/Sex: 15-17 Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex Disaggregates		
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	0
	By type of service: Sexual Violence (Post-Rape Care)	0	0
	By PEP service provision (related to sexual violence services provided)	0	0
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	14,125	41,155
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9	0	0
	By Age: 10-14	1,928	1,589
	By Age: 15-19	3,393	7,556
	By Age: 20-24	2,710	7,247
By Age: 25+	6,094	24,763	
Sum of Age disaggregates	14,125	41,155	



OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	721	721
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	46,519	32,080
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		



	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		



	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age		



	and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS		



	countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic		



	Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,640	8,640
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		



	By age/sex: 18-24 Male		
	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		
	By age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education		



	Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex:		



	Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social		



	Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	64,660	



	By Age/Sex: <15 Female	2,966	
	By Age/Sex: <15 Male	2,572	
	By Age/Sex: 15+ Female	38,155	
	By Age/Sex: 15+ Male	20,967	
	Sum of Age/Sex disaggregates	64,660	
	By Age: <15	5,538	
	By Age: 15+	59,122	
	Sum of Age disaggregates	64,660	
	By Sex: Female	41,121	
	By Sex: Male	23,539	
	Sum of Sex disaggregates	64,660	
	Number of HIV-positive individuals receiving a minimum of one clinical service	5,810	
C2.1.D_NA	By Age/Sex: <15 Female	158	
	By Age/Sex: <15 Male	220	
	By Age/Sex: 15+ Female	2,959	
	By Age/Sex: 15+ Male	2,473	
	Sum of Age/Sex disaggregates	5,810	
	By Age: <15	378	
	By Age: 15+	5,432	
	Sum of Age disaggregates	5,810	
	By Sex: Female	3,117	
	By Sex: Male	2,693	
	Sum of Sex disaggregates	5,810	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	99,544	
	By Age/Sex: <15 Female	4,543	



	By Age/Sex: <15 Male	4,176	
	By Age/Sex: 15+ Female	58,172	
	By Age/Sex: 15+ Male	32,653	
	Sum of Age/Sex disaggregates	99,544	
	By Age: <15	8,719	
	By Age: 15+	90,825	
	Sum of Age disaggregates	99,544	
	By Sex: Female	62,715	
	By Sex: Male	36,829	
	Sum of Sex disaggregates	99,544	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	20,679	
	By Age/Sex: <15 Female	874	
	By Age/Sex: <15 Male	760	
	By Age/Sex: 15+ Female	12,985	
	By Age/Sex: 15+ Male	6,060	
	Sum of Age/Sex disaggregates	20,679	
	By Age: <15	1,634	
	By Age: 15+	19,045	
	Sum of Age disaggregates	20,679	
	By Sex: Female	13,859	
	By Sex: Male	6,820	
	Sum of Sex disaggregates	20,679	
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	128 %	
	Number of HIV-positive	83,000	



	patients who were screened for TB in HIV care or treatment setting		
	Number of HIV-positive individuals receiving a minimum of one clinical service	64,660	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		105,929
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		0
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		0
	Age/sex: 20-24 Male		0
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		0
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		0
	Age/sex: 25-49 Female		0
	Age/sex: 50+ Female		0
	Sun of Age/Sex disaggregates		0
	Aggregated Age/sex - USE WITH HQ PERMISSION		0



	ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		0
	Sum of Aggregated Age/Sex disaggregates		0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		0
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		0
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		0
	Age/sex: 20-24 Male		0
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		0
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		0
	Age/sex: 25-49 Female		0



	Age/sex: 50+ Female		0
	Sum of Age/Sex disaggregates		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		0
	Sum of Aggregated Age/Sex disaggregates		0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		17,500
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		0
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		0
	Age/sex: 20-24 Male		0
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0



	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		0
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		0
	Age/sex: 25-49 Female		0
	Age/sex: 50+ Female		0
	Sum of Age/sex disaggregates		0
	Aggregated Age/sex: <15 Male		0
	Aggregated Age/sex: 15+ Male		0
	Aggregated Age/sex: <15 Female		0
	Aggregated Age/sex: 15+ Female		0
	Sum of Aggregated Age/sex disaggregates		0
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	n/a	
	Number of PEPFAR-supported HIV clinical care sites at which at	0	118



	least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
	Total number of PEPFAR supported sites providing clinical care services	0	147
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	48
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND	0	70



	3) if eligible, cotrimoxazole		
	Sum of Numerator Site Support Type disaggregates	0	118
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	60
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	0	87
	Sum of Denominator Site Support Type disaggregates	0	147
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition	n/a	
	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		67
	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		112
	By site support type: Direct Service Delivery (DSD):		31



	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		36
	Sum of Numerator Support Type disaggregates		67
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		52
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		60
	Sum of Denominator Support Type disaggregates		112
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary	100 %	



	food		
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	613	392
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	613	392
	Age: <1	0	0
	Age: 1-4	18	0
	Age: 5-14	111	0
	Age: 15-17	51	0
	Age: 18+	433	0
	Sum of Age disaggregates	613	0
	Aggregated Age: <18	180	0
	Aggregated Age: 18+	433	0
	Sum of Aggregated Age disaggregates	613	0
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	4,315



	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	0
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male	0	0
	Female	0	0
	Sum of Sex disaggregates	0	0
	Newly tested	0	0
	Known HIV-positive	0	0
	Sum of Test Status disaggregates	0	0
	Aggregated Age: <15		0
	Aggregated Age: 15+	0	0
	Sum of Aggregated Age disaggregates	0	0
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ARTSITE	TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases	77 %	



	who are HIV-positive are on ART		
	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	41	46
	The number of PEPFAR-supported TB basic management units	53	56
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1	6
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	40	40
	Sum of Numerator Site Support Type disaggregates	41	46
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic	8	8



	management units		
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	45	48
	Sum of Denominator Site Support Type disaggregates	53	56
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		75,945
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		105,929
	Age: <1		1,487
	Age: 1-4		2,029
	Age: 5-9		1,393
	Age: 10-14		1,263
	Age: 15-19		1,813
	Age: 20+		
	Sum of Age disaggregates		7,985
Aggregated Age - USE WITH HQ PERMISSION ONLY:		6,171	



	<15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		69,774
	Sum of Aggregated Age disaggregates		75,945
	Sex: Male		28,455
	Sex: Female		47,490
	Sum of Sex disaggregates		75,945
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	95 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	9,833	10,187
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,351	10,496
	By infants who received a virologic test within 2 months of birth	8,358	9,168
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,475	1,019
	Sum of Infant Age disaggregates	9,833	10,187
	By infants with a positive virologic test result within 12	492	408



	months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	69,934	88,429
	Age/Sex: <1 Male	656	0
	Age/Sex: 1-4 Male	945	0
	Age/Sex: 5-14 Male	1,202	0
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	819	0
	Age/Sex: 1-4 Female	1,070	0
	Age/Sex: 5-14 Female	1,434	0
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	656	0
	Aggregated Age/Sex: <1 Female	819	0
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	23,240	0
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	40,568	0
	Sum of Aggregated Age/Sex <15	6,126	0



	Sum of Aggregated Age/Sex 15+	63,808	0
	Sum of Aggregated Age/Sex disaggregates	69,934	0
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: <15 Male		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: <15 Female		
	Aggregated Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
Sum of Aggregated Age/Sex			



	disaggregations		
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	81,557	89,631
	Age/Sex: <1 Male	869	934
	Age/Sex: 1-4 Male	1,094	1,177
	Age/Sex: 5-14 Male	1,360	1,460
	Age/Sex: 15+ Male	26,497	29,205
	Age/Sex: <1 Female	1,146	1,239
	Age/Sex: 1-4 Female	1,251	1,355
	Age/Sex: 5-14 Female	1,645	1,772
	Age/Sex: 15+ Female	47,695	52,489
	Sum of Age/Sex disaggregates	81,557	89,631
	Aggregated Age/Sex: <1 Male	853	904
	Aggregated Age/Sex: <1 Female	1,143	1,214
	Aggregated Age/Sex: <15 Male	3,495	3,702
	Aggregated Age/Sex: 15+ Male	26,918	29,915
	Aggregated Age/Sex: <15 Female	4,235	4,510
	Aggregated Age/Sex: 15+ Female	46,909	51,504
	Sum of Aggregated Age/Sex disaggregates	81,557	89,631
	Sum of Aggregated Age/Sex <15	7,730	8,212
	Sum of Aggregated Age/Sex 15+	73,827	81,419
	TX_CURR_TA	Number of adults and children receiving	9,606



	antiretroviral therapy (ART)		
	Age/Sex: <1 Male	203	0
	Age/Sex: 1-4 Male	134	0
	Age/Sex: 5-14 Male	110	0
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	322	0
	Age/Sex: 1-4 Female	166	0
	Age/Sex: 5-14 Female	155	0
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations	1,090	0
	Aggregated Age/Sex: <1 Male	217	0
	Aggregated Age/Sex: <1 Female	388	0
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	3,176	0
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	5,198	0
	Sum of Aggregated Age/Sex <15	1,232	0
	Sum of Aggregated Age/Sex 15+	8,374	0
	Sum of Aggregated Age/Sex disaggregates	9,606	0
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR	100 %	



	supported with documented routine supportive supervision visits to 75% of ART sites in District		
	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4
	Total number of PEPFAR supported District Health Offices	4	4
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,878	14,000
	By Age/Sex: <1 Male	113	0
	By Age/Sex: 1-4 Male	173	0
	By Age/Sex: 5-9 Male	143	0
	By Age/Sex: 10-14 Male	130	0
	By Age/Sex: 15-19 Male	56	0
	By Age/Sex: 20-24 Male	230	0
	By Age/Sex: 25-49 Male	3,385	0
	By Age/Sex: 50+ Male	676	0
	By Age/Sex: <1 Female	155	0
	By Age/Sex: 1-4 Female	214	0
	By Age/Sex: 5-9 Female	143	0
	By Age/Sex: 10-14 Female	149	0
	By Age/Sex: 15-19 Female	236	0
	By Age/Sex: 20-24 Female	933	0
	By Age/Sex: 25-49 Female	4,513	0
	By Age/Sex: 50+ Female	629	0
	Sum of Age/Sex disaggregates	11,878	0



	Aggregated Grouping by Age: <1 Male	14	0
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	5,148	0
	Aggregated Grouping by Age/Sex: <1 Female	28	0
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	4,979	0
	Sum of Aggregated Age/Sex disaggregates	11,839	0
	Pregnancy status		
	Breastfeeding status		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	87 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,438	9,672
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,699	10,507
	Age/Sex: <5 Male (Numerator: Number of		



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of		



	adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,		



	including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number		



	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	n/a	
	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		123



	Total number of PEPFAR-supported ART sites		123
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		60
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		63
	Sum of Numerator Site Support Type disaggregates		123
	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites		60
	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites		63
	Sum of Denominator Site Support Type disaggregates		123
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that		8



	are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	130	150
	By clinical laboratories	14	14
	By Point-of-care testing sites	116	136
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		100
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		150
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		130
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		130



	CD4: Number of laboratories that perform this testing		36
	CD4: Number of laboratories that participate in this PT program		36
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		25
	Early infant diagnostics: Number of laboratories that perform this testing		1
	Early infant diagnostics: Number of laboratories that participate in this PT program		1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	HIV viral load: Number of laboratories that perform this testing		1
	HIV viral load: Number of laboratories that participate in this PT program		1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this		



	testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of		



	laboratories that achieve acceptable successful passing criteria in this PT program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	277	275
	By Graduates: Doctors	0	1
	By Graduates: Nurses	187	186
	By Graduates: Midwives	65	64
	By Graduates: Social service workers	0	0
	By Graduates: Laboratory professionals	4	0
	By Graduates: Other	21	24
	Sum of Graduates disaggreagtes	277	275
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	n/a	
	Number of individuals who received competency-based, certificate or higher-level training to conduct or support		176



	supply chain, inventory management, supportive supervision or distribution activities		
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities		300
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program		22
	By: Individuals who passed a competency-based training to conduct supply chain activities		160
	By: Individuals who passed a competency-based training to perform inventory management		160
	By: Individuals who passed a competency-based training to develop distribution plans		160
	By: Individuals who passed a competency-based training to perform supportive supervision		16
	By: Individuals who passed a competency-based training to perform quantification		160
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of	n/a	



	HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services		
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	137
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	147
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months	100 %	
	Number of PEPFAR-supported clinical	163	163



	service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	52	52
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	111	111
	Sum of Numerator Site Support Type disaggregates	163	163
	By site support type: Direct Service Delivery (DSD):	0	0



	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163
	Sum of Denominator Site Support Type disaggregates	163	163
SC_STOCK	SC_STOCK Storage sites which stock commodities according to plan	60 %	
	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	4,152	1,650
	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	6,920	1,736
	System Level: Central Medical Stores	8	24

Approved



	System Level: Regional Medical Stores	0	0
	System Level: District	0	0
	System Level: Health facility	1,728	684
	Commodity: Condoms	1,728	12
	Commodity: ARV drugs	1,728	504
	Commodity: Rapid test kits	1,728	192
	Commodity: OI drugs	1,728	504
	Commodity: Other	1,728	12



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10157	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	1,156,997
10247	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10703	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,181,134
11673	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	750,000
13144	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13357	New York AIDS Institute	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and	GHP-State	25,000



			Services Administration		
13630	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
13645	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	1,000,000
13738	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
13742	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	800,000
13791	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,602,560
14201	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-State	1,250,000
14374	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



14842	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
16760	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	1,375,000
16815	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	940,000
16821	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	2,000,000
17389	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	77,240
17454	TBD	TBD	Redacted	Redacted	Redacted
17455	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
17458	TBD	TBD	Redacted	Redacted	Redacted
17460	TBD	TBD	Redacted	Redacted	Redacted
17461	TBD	TBD	Redacted	Redacted	Redacted
17462	TBD	TBD	Redacted	Redacted	Redacted
17463	TBD	TBD	Redacted	Redacted	Redacted
17464	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,956,724
17465	TBD	TBD	Redacted	Redacted	Redacted
17548	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	1,032,458
17555	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	50,000
17559	Regional	Other USG	U.S. Department	GHP-State	500,000

Approved



	Procurement Support Office/Frankfurt	Agency	of State/Bureau of African Affairs		
17572	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17775	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	2,450,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17775	Mechanism Name: Building Local Capacity (BLC)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,450,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,450,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17775



Mechanism Name: Building Local Capacity (BLC)			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	640,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	65,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	432,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	248,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	225,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	65,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17572	Mechanism Name: TA Support for the Strengthening of Blood Transfusion
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	100,000

Sub Partner Name(s)

None		
------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Safe Motherhood



Budget Code Information

Mechanism ID:	17572		
Mechanism Name:	TA Support for the Strengthening of Blood Transfusion		
Prime Partner Name:	American Association of Blood Banks		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17559	Mechanism Name: RPSO-Supported Renovation Projects in Swaziland MOH Facilities
Funding Agency: State/AF	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Renovation	500,000
------------	---------



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17559		
Mechanism Name:	RPSO-Supported Renovation Projects in Swaziland MOH Facilities		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17555	Mechanism Name: USDF MeHIN
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 50,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	50,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Military Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	17555		
Mechanism Name:	USDF MeHIN		
Prime Partner Name:	VISTA PARTNERS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17548	Mechanism Name: Supply Chain Management System (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,032,458	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 57,542	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,032,458

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17548			
Mechanism Name: Supply Chain Management System (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	242,458	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	190,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17465	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17464	Mechanism Name: TBD PACT follow on
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 1,956,724	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 331,376	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,956,724

Sub Partner Name(s)

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Education	200,000
Condom programming	150,000
Economic Strengthening	200,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17464			
Mechanism Name: TBD PACT follow on			
Prime Partner Name: Pact			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,556,724	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17463	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17462	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17461	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17460	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17458	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17455	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 17455			
Mechanism Name: PEPFAR Small Grants Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17454	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17389	Mechanism Name: Vast Grants
Funding Agency: PC	Procurement Type: Grant
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 77,240	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount



GHP-State	77,240
-----------	--------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	27,037
Economic Strengthening	15,448
Education	15,448
Water	7,724
Condom programming	3,862
Gender: GBV	1,931
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	5,793
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support

Key Issues

Child Survival Activities

Mobile Population

Safe Motherhood

Family Planning



Budget Code Information

Mechanism ID: 17389			
Mechanism Name: Vast Grants			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	72,240	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	3,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	65	65
OVC_SERV_DSD	Sex: Male	700	750
OVC_SERV_DSD	Sex: Female	800	850
OVC_SERV_DSD	Sum of Sex disaggregates	1,500	1,600
OVC_SERV_DSD	Age: <1	0	0
OVC_SERV_DSD	Age: 1-4	0	0
OVC_SERV_DSD	Age: 5-9	150	160
OVC_SERV_DSD	Age: 10-14	450	480
OVC_SERV_DSD	Age: 15-17	450	480
OVC_SERV_DSD	Age: 18+	450	480
OVC_SERV_DSD	Sum of Age disaggregates	1,500	1,600

Implementing Mechanism Details



Mechanism ID: 16821	Mechanism Name: Health Communication Capacity Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 37,992	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,000,000

Sub Partner Name(s)

Family Life Association of Swaziland	Management Science for Health	Population Services International
--------------------------------------	-------------------------------	-----------------------------------

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	30,000



Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16821			
Mechanism Name: Health Communication Capacity Collaborative (HC3)			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	30	
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	6	12
PP_PREV_DSD	Total number of people in the target population	271,104	
PP_PREV_DSD	Age/sex: 15-19 Male	26,784	
PP_PREV_DSD	Age/sex: 20-24 Male	26,784	
PP_PREV_DSD	Age/sex: 25-49 Male	35,712	
PP_PREV_DSD	Age/sex: 15-19 Female	26,784	
PP_PREV_DSD	Age/sex: 20-24 Female	26,784	
PP_PREV_DSD	Age/sex: 25-49 Female	35,712	
PP_PREV_DSD	Sum of Age/Sex disaggregates	178,560	
PP_PREV_TA	Total number of people in the target population	68,488	
PP_PREV_TA	Age/sex: 15-19 Male	1,215	



PP_PREV_TA	Age/sex: 20-24 Male	1,215	
PP_PREV_TA	Age/sex: 25-49 Male	1,620	
PP_PREV_TA	Age/sex: 15-19 Female	1,215	
PP_PREV_TA	Age/sex: 20-24 Female	1,215	
PP_PREV_TA	Age/sex: 25-49 Female	1,620	
PP_PREV_TA	Sum of Age/Sex disaggregates	8,100	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	332	300
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	132	200
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	100
GEND_NORM_DSD	By Age: 15-19	300	5,580
GEND_NORM_DSD	By Age: 20-24	300	5,580
GEND_NORM_DSD	By Age: 25+	1,200	22,320
GEND_NORM_DSD	Sum of Age disaggregates	1,800	33,480
GEND_NORM_DSD	By Sex: Male	900	16,740
GEND_NORM_DSD	By Sex: Female	900	16,740
GEND_NORM_DSD	Sum of Sex disaggregates	1,800	33,480
GEND_NORM_DSD	By type of activity: Small Group	1,800	33,480

Implementing Mechanism Details



Mechanism ID: 16815	Mechanism Name: Health Finance & Governance Project (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 940,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 546,351	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	940,000

Sub Partner Name(s)

Training Resources Group		
--------------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	440,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16815		
Mechanism Name:	Health Finance & Governance Project (HFG)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	619,807	0
Governance and Systems	OHSS	320,193	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,640	

Implementing Mechanism Details

Mechanism ID: 16760	Mechanism Name: URC-ASSIST
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,375,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-USAID	1,375,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Renovation	13,870

Key Issues

- Child Survival Activities
- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- End-of-Program Evaluation

Budget Code Information

Mechanism ID: 16760			
Mechanism Name: URC-ASSIST			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	865,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	209,113	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	53	53
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	10	10
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	76	76
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	53	53
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	13,280	
C2.1.D_DSD	By Age/Sex: <15 Female	362	
C2.1.D_DSD	By Age/Sex: <15 Male	503	
C2.1.D_DSD	By Age/Sex: 15+ Female	6,764	
C2.1.D_DSD	By Age/Sex: 15+ Male	5,651	
C2.1.D_DSD	Sum of Age/Sex disaggregates	13,280	
C2.1.D_DSD	By Age: <15	865	
C2.1.D_DSD	By Age: 15+	12,415	



C2.1.D_DSD	Sum of Age disaggregates	13,280	
C2.1.D_DSD	By Sex: Female	6,694	
C2.1.D_DSD	By Sex: Male	6,586	
C2.1.D_DSD	Sum of Sex disaggregates	13,280	
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	5,810	6,391
C2.1.D_NA	By Age/Sex: <15 Female	158	174
C2.1.D_NA	By Age/Sex: <15 Male	220	242
C2.1.D_NA	By Age/Sex: 15+ Female	2,959	3,255
C2.1.D_NA	By Age/Sex: 15+ Male	2,472	2,720
C2.1.D_NA	Sum of Age/Sex disaggregates	5,809	6,391
C2.1.D_NA	By Age: <15	378	418
C2.1.D_NA	By Age: 15+	5,432	5,973
C2.1.D_NA	Sum of Age disaggregates	5,810	6,391
C2.1.D_NA	By Sex: Female	3,117	2,894
C2.1.D_NA	By Sex: Male	2,693	3,497
C2.1.D_NA	Sum of Sex disaggregates	5,810	6,391
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	83,000	91,300
C2.1.D_NGI	By Age/Sex: <15 Female	2,264	2,590
C2.1.D_NGI	By Age/Sex: <15 Male	3,141	3,470
C2.1.D_NGI	By Age/Sex: 15+ Female	42,275	46,430
C2.1.D_NGI	By Age/Sex: 15+ Male	35,320	38,810
C2.1.D_NGI	Sum of Age/Sex disaggregates	83,000	91,300
C2.1.D_NGI	By Age: <15	5,405	6,060
C2.1.D_NGI	By Age: 15+	77,595	85,240
C2.1.D_NGI	Sum of Age disaggregates	83,000	91,300
C2.1.D_NGI	By Sex: Female	44,539	49,020
C2.1.D_NGI	By Sex: Male	38,461	42,280
C2.1.D_NGI	Sum of Sex disaggregates	83,000	91,300
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	63,910	70,301



C2.1.D_TA	By Age/Sex: <15 Female	1,743	2,017
C2.1.D_TA	By Age/Sex: <15 Male	2,419	2,675
C2.1.D_TA	By Age/Sex: 15+ Female	32,552	35,734
C2.1.D_TA	By Age/Sex: 15+ Male	27,196	29,874
C2.1.D_TA	Sum of Age/Sex disaggregates	63,910	70,300
C2.1.D_TA	By Age: <15	4,162	4,691
C2.1.D_TA	By Age: 15+	59,748	65,610
C2.1.D_TA	Sum of Age disaggregates	63,910	70,301
C2.1.D_TA	By Sex: Female	34,728	37,988
C2.1.D_TA	By Sex: Male	29,182	32,313
C2.1.D_TA	Sum of Sex disaggregates	63,910	70,301
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	83,000	91,300
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	13,280	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	595	
CARE_CURR_DSD	Age/sex: <1 Male	1	
CARE_CURR_DSD	Age/sex: 1-4 Male	5	
CARE_CURR_DSD	Age/sex: 5-9 Male	10	
CARE_CURR_DSD	Age/sex: 10-14 Male	10	
CARE_CURR_DSD	Age/sex: 15-19 Male	20	
CARE_CURR_DSD	Age/sex: 20-24 Male	25	
CARE_CURR_DSD	Age/sex: 25-49 Male	151	
CARE_CURR_DSD	Age/sex: 50+ Male	54	
CARE_CURR_DSD	Age/sex: <1 Female	1	
CARE_CURR_DSD	Age/sex: 1-4 Female	5	
CARE_CURR_DSD	Age/sex: 5-9 Female	5	
CARE_CURR_DSD	Age/sex: 10-14 Female	6	



CARE_CURR_DSD	Age/sex: 15-19 Female	21	
CARE_CURR_DSD	Age/sex: 20-24 Female	37	
CARE_CURR_DSD	Age/sex: 25-49 Female	157	
CARE_CURR_DSD	Age/sex: 50+ Female	87	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	595	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	271	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	296	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	595	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,000	6,050
CARE_NEW_DSD	Age/sex: <1 Male	10	20
CARE_NEW_DSD	Age/sex: 1-4 Male	50	101
CARE_NEW_DSD	Age/sex: 5-9 Male	30	61
CARE_NEW_DSD	Age/sex: 10-14 Male	30	60
CARE_NEW_DSD	Age/sex: 15-19 Male	60	121
CARE_NEW_DSD	Age/sex: 20-24 Male	85	171
CARE_NEW_DSD	Age/sex: 25-49 Male	1,055	2,128
CARE_NEW_DSD	Age/sex: 50+ Male	267	539
CARE_NEW_DSD	Age/sex: <1 Female	10	20
CARE_NEW_DSD	Age/sex: 1-4 Female	68	137
CARE_NEW_DSD	Age/sex: 5-9 Female	30	61
CARE_NEW_DSD	Age/sex: 10-14 Female	30	61
CARE_NEW_DSD	Age/sex: 15-19 Female	70	141



CARE_NEW_DSD	Age/sex: 20-24 Female	140	282
CARE_NEW_DSD	Age/sex: 25-49 Female	900	1,815
CARE_NEW_DSD	Age/sex: 50+ Female	165	333
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,000	6,051
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	120	242
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,467	2,959
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	138	278
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,275	2,571
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,000	6,050
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	27	25
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	30	27
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	2	2
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	25	23
CARE_SITE	Sum of Numerator Site Support Type	27	25



	disaggregates		
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	2	2
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	28	25
CARE_SITE	Sum of Denominator Site Support Type disaggregates	30	27
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,495	2,700
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,288	3,000
TB_ART_DSD	Age: 0-4	264	135
TB_ART_DSD	Age: 5-14	209	108
TB_ART_DSD	Age: 15+	4,022	2,457
TB_ART_DSD	Male	2,382	1,431
TB_ART_DSD	Female	2,113	1,269
TB_ART_DSD	Sum of Sex disaggregates	4,495	2,700
TB_ART_DSD	Newly tested	1,586	900
TB_ART_DSD	Known HIV-positive	3,702	2,100
TB_ART_DSD	Sum of Test Status disaggregates	5,288	3,000
TB_ART_DSD	Aggregated Age: <15	473	243
TB_ART_DSD	Aggregated Age: 15+	4,022	2,457
TB_ART_DSD	Sum of Aggregated Age disaggregates	4,495	2,700
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	86	86



TB_ARTSITE	The number of PEPFAR-supported TB basic management units	86	86
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1	6
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	40	40
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	41	46
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	8	8
TB_ARTSITE	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units	45	48
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	53	56
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	849	600
TX_CURR_DSD	Age/Sex: <1 Male	1	3
TX_CURR_DSD	Age/Sex: 1-4 Male	4	11
TX_CURR_DSD	Age/Sex: 5-14 Male	12	12
TX_CURR_DSD	Age/Sex: 15+ Male	425	278
TX_CURR_DSD	Age/Sex: <1 Female	2	3
TX_CURR_DSD	Age/Sex: 1-4 Female	5	13
TX_CURR_DSD	Age/Sex: 5-14 Female	10	12
TX_CURR_DSD	Age/Sex: 15+ Female	390	268



TX_CURR_DSD	Sum of age/sex disaggregates	34	54
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	4	5
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	48	49
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1	3
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	2	3
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	19	26
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	425	278
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	15	28
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	390	268
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	34	54
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	815	546
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	849	600
TX_CURR_NA	Number of adults and children receiving antiretroviral therapy (ART)	442	
TX_CURR_NA	Age/Sex: <1 Male	1	
TX_CURR_NA	Age/Sex: 1-4 Male	4	
TX_CURR_NA	Age/Sex: 5-14 Male	9	
TX_CURR_NA	Age/Sex: 15+ Male	212	
TX_CURR_NA	Age/Sex: <1 Female	1	
TX_CURR_NA	Age/Sex: 1-4 Female	6	
TX_CURR_NA	Age/Sex: 5-14 Female	9	
TX_CURR_NA	Age/Sex: 15+ Female	200	
TX_CURR_NA	Sum of Age/Sex disaggregates	442	
TX_CURR_NA	Aggregated Age/Sex: <1 Male	1	
TX_CURR_NA	Aggregated Age/Sex: <1 Female	6	
TX_CURR_NA	Aggregated Age/Sex: <15 Male	13	
TX_CURR_NA	Aggregated Age/Sex: 15+ Male	212	
TX_CURR_NA	Aggregated Age/Sex: <15 Female	15	



TX_CURR_NA	Aggregated Age/Sex: 15+ Female	202	
TX_CURR_NA	Sum of Aggregated Age/Sex <15	28	
TX_CURR_NA	Sum of Aggregated Age/Sex 15+	414	
TX_CURR_NA	Sum of Aggregated Age/Sex disaggregations	442	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	5,100	2,974
TX_CURR_NGI	Age/Sex: <1 Male	8	4
TX_CURR_NGI	Age/Sex: 1-4 Male	50	25
TX_CURR_NGI	Age/Sex: 5-14 Male	100	49
TX_CURR_NGI	Age/Sex: 15+ Male	2,450	1,416
TX_CURR_NGI	Age/Sex: <1 Female	10	5
TX_CURR_NGI	Age/Sex: 1-4 Female	72	34
TX_CURR_NGI	Age/Sex: 5-14 Female	108	54
TX_CURR_NGI	Age/Sex: 15+ Female	2,302	1,387
TX_CURR_NGI	Sum of Age/Sex disaggregates	5,100	2,974
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	1	4
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	10	5
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	158	78
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,450	1,416
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	190	93
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	2,302	1,387
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	5,100	2,974
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	348	171
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	4,752	2,803
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,250	2,125
TX_CURR_TA	Age/Sex: <1 Male	6	3
TX_CURR_TA	Age/Sex: 1-4 Male	42	21
TX_CURR_TA	Age/Sex: 5-14 Male	78	37
TX_CURR_TA	Age/Sex: 15+ Male	1,982	991
TX_CURR_TA	Age/Sex: <1 Female	6	3
TX_CURR_TA	Age/Sex: 1-4 Female	63	29



TX_CURR_TA	Age/Sex: 5-14 Female	79	44
TX_CURR_TA	Age/Sex: 15+ Female	1,994	997
TX_CURR_TA	Sum of Age/Sex disaggregations	274	137
TX_CURR_TA	Aggregated Age/Sex: <1 Male	6	3
TX_CURR_TA	Aggregated Age/Sex: <1 Female	6	3
TX_CURR_TA	Aggregated Age/Sex: <15 Male	134	61
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,982	991
TX_CURR_TA	Aggregated Age/Sex: <15 Female	140	76
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,994	997
TX_CURR_TA	Sum of Aggregated Age/Sex <15	274	137
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,976	1,988
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,250	2,125
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4
TX_DIST	Total number of PEPFAR supported District Health Offices	4	4
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,886	939
TX_NEW_DSD	By Age/Sex: <1 Male	5	2
TX_NEW_DSD	By Age/Sex: 1-4 Male	23	20
TX_NEW_DSD	By Age/Sex: 5-9 Male	20	10
TX_NEW_DSD	By Age/Sex: 10-14 Male	18	9
TX_NEW_DSD	By Age/Sex: 15-19 Male	54	17
TX_NEW_DSD	By Age/Sex: 20-24 Male	30	30
TX_NEW_DSD	By Age/Sex: 25-49 Male	550	272
TX_NEW_DSD	By Age/Sex: 50+ Male	167	83
TX_NEW_DSD	By Age/Sex: <1 Female	7	3
TX_NEW_DSD	By Age/Sex: 1-4 Female	44	22
TX_NEW_DSD	By Age/Sex: 5-9 Female	24	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	20	9



TX_NEW_DSD	By Age/Sex: 15-19 Female	63	26
TX_NEW_DSD	By Age/Sex: 20-24 Female	92	40
TX_NEW_DSD	By Age/Sex: 25-49 Female	671	337
TX_NEW_DSD	By Age/Sex: 50+ Female	98	49
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,886	939
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	5	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	66	43
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	801	450
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	7	3
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	95	46
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	924	400
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,886	939
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	53	60
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	53	60
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	8	8
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has	45	52



	documented results in the last 6 months		
QI_SITE	Sum of Numerator Site Support Type disaggregates	53	60
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	8	8
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	45	52
QI_SITE	Sum of Denominator Site Support Type disaggregates	53	60
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	83,000	91,300
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	595	

Implementing Mechanism Details

Mechanism ID: 14842	Mechanism Name: Public Diplomacy
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	

Approved



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14842			
Mechanism Name: Public Diplomacy			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14374	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 200,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Malaria (PMI)
Military Population

Budget Code Information

Mechanism ID:	14374		
Mechanism Name:	APHL		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14201	Mechanism Name: M2M (Mothers 2 Mothers)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Motor Vehicles: Purchased	25,000



Gender: Gender Equality	25,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Water	50,000

Key Issues

- Child Survival Activities
- Safe Motherhood
- Family Planning

Budget Code Information

Mechanism ID: 14201			
Mechanism Name: M2M (Mothers 2 Mothers)			
Prime Partner Name: Mothers 2 Mothers			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	168,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	712,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	168,750	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	12,200	12,200
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,611	13,611
PP_PREV_DSD	Total number of people in the target population	14,000	14,000
PP_PREV_DSD	Age/sex: 25-49 Female	13,611	13,611
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,611	13,611

Implementing Mechanism Details

Mechanism ID: 13791	Mechanism Name: PSI-CIHTC (Client-initiated HIV Testing & Counseling)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,602,560	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 307,438	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,602,560

Sub Partner Name(s)



Adra		
------	--	--

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	15,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	15,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Human Resources for Health	27,000

Key Issues

- Mobile Population
- TB
- Workplace Programs



End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13791		
Mechanism Name:	PSI-CIHTC (Client-initiated HIV Testing & Counseling)		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,452,560	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	195	212	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	195	212	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	4	5	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,000	12,100	Redacted
PP_PREV_DSD	Total number of people in the target	324,484	324,484	Redacted



	population			
PP_PREV_DSD	Age/sex: 10-14 Male	1,510	1,661	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,725	2,998	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,210	1,331	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	605	665	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,240	1,364	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,230	2,453	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	990	1,089	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	490	539	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,000	12,100	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	300	400	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200	250	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	150	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,000	83,600	Redacted



HTC_TST_DSD	By Test Result: Negative	68,400	75,240	Redacted
HTC_TST_DSD	By Test Result: Positive	7,600	8,360	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	76,000	83,600	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,520	2,508	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,280	2,508	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	7,600	16,720	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,080	836	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,800	6,688	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,960	20,064	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	760	836	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,520	836	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,280	2,508	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	7,600	4,180	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,080	5,016	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,800	4,180	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	15,960	15,884	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	760	836	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	76,000	83,600	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,400	21,736	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,600	28,424	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,400	7,524	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,600	25,916	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	22,800	29,260	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	53,200	54,340	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	76,000	83,600	Redacted



HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,000	83,600	Redacted
HTC_TST_NGI	By Test Result: Negative	68,400	75,240	Redacted
HTC_TST_NGI	By Test Result: Positive	7,600	8,360	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	76,000	83,600	Redacted
HTC_TST_NGI	Age/sex: <1 Male	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,520	2,508	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	2,280	2,508	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	7,600	16,720	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	6,080	836	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	3,800	6,688	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	15,960	20,064	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	760	836	Redacted
HTC_TST_NGI	Age/sex: <1 Female	0	0	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,520	836	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	2,280	2,508	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	7,600	4,180	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	6,080	5,016	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	3,800	4,180	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	15,960	15,884	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	760	836	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	76,000	83,600	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	11,400	21,736	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	26,600	28,424	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	11,400	7,524	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	26,600	25,916	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	22,800	29,260	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	53,200	54,340	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	76,000	83,600	Redacted

Implementing Mechanism Details



Mechanism ID: 13742	Mechanism Name: C-BLD (Capacity Building and Livelihoods Development)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 800,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-USAID	800,000

Sub Partner Name(s)

TechnoServe		
-------------	--	--

Cross-Cutting Budget Attribution(s)

Economic Strengthening	330,000
Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	100,000



Key Issues

Child Survival Activities

Budget Code Information

Mechanism ID:	13742		
Mechanism Name:	C-BLD (Capacity Building and Livelihoods Development)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	800,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,211	3,717
PP_PREV_DSD	Total number of people in the target population	23,654	24,567
PP_PREV_DSD	Age/sex: 10-14 Male	700	837
PP_PREV_DSD	Age/sex: 15-19 Male	365	474
PP_PREV_DSD	Age/sex: 20-24 Male	409	424
PP_PREV_DSD	Age/sex: 25-49 Male	40	20
PP_PREV_DSD	Age/sex: 10-14 Female	829	1,038
PP_PREV_DSD	Age/sex: 15-19 Female	426	456
PP_PREV_DSD	Age/sex: 20-24 Female	402	448
PP_PREV_DSD	Age/sex: 25-49 Female	40	20



PP_PREV_DSD	Sum of Age/Sex disaggregates	3,211	3,717
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	0
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	1,450	1,500
GEND_NORM_DSD	By Age: 15-19	1,350	1,650
GEND_NORM_DSD	By Age: 20-24	1,250	1,450
GEND_NORM_DSD	By Age: 25+	1,450	1,800
GEND_NORM_DSD	Sum of Age disaggregates	5,500	6,400
GEND_NORM_DSD	By Sex: Male	2,200	2,500
GEND_NORM_DSD	By Sex: Female	3,300	3,900
GEND_NORM_DSD	Sum of Sex disaggregates	5,500	6,400
GEND_NORM_DSD	By type of activity: Individual	430	350
GEND_NORM_DSD	By type of activity: Small Group	2,500	2,500
GEND_NORM_DSD	By type of activity: Community-level	1,500	3,550
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,380	11,070
OVC_SERV_DSD	Sex: Male	3,026	4,539
OVC_SERV_DSD	Sex: Female	4,354	6,531
OVC_SERV_DSD	Sum of Sex disaggregates	7,380	11,070
OVC_SERV_DSD	Age: <1	960	1,440
OVC_SERV_DSD	Age: 1-4	970	1,455
OVC_SERV_DSD	Age: 5-9	1,230	1,845
OVC_SERV_DSD	Age: 10-14	1,320	1,980
OVC_SERV_DSD	Age: 15-17	1,670	2,505
OVC_SERV_DSD	Age: 18+	1,230	1,845
OVC_SERV_DSD	Sum of Age disaggregates	7,380	11,070

Implementing Mechanism Details

Mechanism ID: 13738	Mechanism Name: EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)
----------------------------	--

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 375,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 190,750	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	375,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Key Issues

Child Survival Activities

TB

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13738		
Mechanism Name:	EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	20	20	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	143	143	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	8	144	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	144	144	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	144	144	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	144	144	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	70,923	80,197	Redacted



	test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	58,684	66,893	Redacted
HTC_TST_DSD	By Test Result: Positive	12,239	13,304	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	70,923	80,197	Redacted
HTC_TST_DSD	Age/sex: <1 Male	916	1,036	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,877	3,253	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,040	1,176	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	566	641	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,374	1,553	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,805	4,302	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	11,305	12,781	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,544	4,006	Redacted
HTC_TST_DSD	Age/sex: <1 Female	707	798	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,224	2,515	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	789	892	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	579	654	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,031	6,818	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	11,718	13,254	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	18,838	21,304	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,610	5,214	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	70,923	80,197	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,401	6,106	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,027	22,643	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,298	4,859	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	41,197	46,589	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,699	10,965	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	61,224	69,232	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex	70,923	80,197	Redacted



	disaggregates			
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	169,624	191,752	Redacted
HTC_TST_NGI	By Test Result: Negative	139,026	158,493	Redacted
HTC_TST_NGI	By Test Result: Positive	30,598	33,259	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	169,624	191,752	Redacted
HTC_TST_NGI	Age/sex: <1 Male	1,796	2,031	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	5,642	6,377	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	2,040	2,306	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,110	1,256	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,694	3,046	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	7,461	8,435	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	22,166	25,058	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	6,949	7,855	Redacted
HTC_TST_NGI	Age/sex: <1 Female	1,859	2,102	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	5,853	6,617	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	2,077	2,384	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	1,523	1,721	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	15,871	17,942	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	30,853	34,877	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	49,594	56,062	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	12,136	13,719	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	169,624	191,788	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	98,701	111,556	Redacted
HTC_TST_TA	By Test Result: Negative	80,342	91,601	Redacted
HTC_TST_TA	By Test Result: Positive	18,359	19,955	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	98,701	111,556	Redacted
HTC_TST_TA	Age/sex: <1 Male	880	995	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	2,765	3,125	Redacted



HTC_TST_TA	Age/sex: 5-9 Male	1,000	1,130	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	545	615	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,320	1,492	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	3,656	4,133	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	10,861	12,277	Redacted
HTC_TST_TA	Age/sex: 50+ Male	3,405	3,849	Redacted
HTC_TST_TA	Age/sex: <1 Female	1,152	1,303	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	3,629	4,102	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,288	1,456	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	944	1,067	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	9,840	11,124	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	19,135	21,623	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	30,755	34,759	Redacted
HTC_TST_TA	Age/sex: 50+ Female	7,526	8,506	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	98,701	111,556	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,189	5,865	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,243	21,751	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,013	7,929	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	67,256	76,011	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	12,202	13,794	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	86,499	97,762	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	98,701	111,556	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	163	163	Redacted



QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	163	163	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	163	163	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	163	163	Redacted

Implementing Mechanism Details



Mechanism ID: 13645	Mechanism Name: EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 1,055,612	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

Alliance of Mayors and Municipal Leaders on HIV/AIDS in Africa		
--	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Renovation	23,000
Food and Nutrition: Policy, Tools, and Service Delivery	110,000
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Water	50,000



Key Issues

Safe Motherhood

Family Planning

Budget Code Information

Mechanism ID: 13645			
Mechanism Name: EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	44,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	618,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	168,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	8	144
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	144	144
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	144	144
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	144	144
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,939	9,451
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,351	10,496
PMTCT_ARV_NGI	Life-long ART (including Option B+)	5,390	6,776
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,796	4,101
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,594	2,675
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	4,503	0
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	46	0
PMTCT_ARV_NGI	Sum of Regimen disaggregates	9,939	6,776
PMTCT_ARV_NGI	Sum of New and Current disaggregates	5,390	6,776
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	9,939	9,451



	mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,351	10,496
PMTCT_ARV_TA	Life-long ART (including Option B+)	5,390	6,776
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,796	4,101
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,594	2,675
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	4,503	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	46	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	9,939	6,776
PMTCT_ARV_TA	Sum of New and Current disaggregates	5,390	6,776
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	123	137
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	144	144
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	123	137



PMTCT_SITE	Sum of Numerator Support Type disaggregates	123	137
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	144	144
PMTCT_SITE	Sum of Denominator Support Type disaggregates	144	144
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,785	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	28,488	
PMTCT_STAT_NGI	By: Known positives at entry	5,519	
PMTCT_STAT_NGI	By: Number of new positives identified	4,832	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	10,351	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,785	27,860
PMTCT_STAT_TA	Number of new ANC and L&D clients	28,488	28,313
PMTCT_STAT_TA	By: Known positives at entry	5,519	5,573
PMTCT_STAT_TA	By: Number of new positives identified	4,832	4,923
PMTCT_STAT_TA	Sum of Positives Status disaggregates	10,351	10,496
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	8,647	9,656
C2.1.D_NGI	By Age/Sex: <15 Female	86	82
C2.1.D_NGI	By Age/Sex: <15 Male	86	81
C2.1.D_NGI	By Age/Sex: 15+ Female	8,332	8,887
C2.1.D_NGI	By Age/Sex: 15+ Male	143	606
C2.1.D_NGI	Sum of Age/Sex disaggregates	8,647	9,656
C2.1.D_NGI	By Age: <15	172	163



C2.1.D_NGI	By Age: 15+	8,475	9,493
C2.1.D_NGI	Sum of Age disaggregates	8,647	9,656
C2.1.D_NGI	By Sex: Female	8,418	8,969
C2.1.D_NGI	By Sex: Male	229	687
C2.1.D_NGI	Sum of Sex disaggregates	8,647	9,656
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	8,647	9,656
C2.1.D_TA	By Age/Sex: <15 Female	86	82
C2.1.D_TA	By Age/Sex: <15 Male	86	81
C2.1.D_TA	By Age/Sex: 15+ Female	8,332	8,887
C2.1.D_TA	By Age/Sex: 15+ Male	143	606
C2.1.D_TA	Sum of Age/Sex disaggregates	8,647	9,656
C2.1.D_TA	By Age: <15	172	163
C2.1.D_TA	By Age: 15+	8,475	9,493
C2.1.D_TA	Sum of Age disaggregates	8,647	9,656
C2.1.D_TA	By Sex: Female	8,418	8,969
C2.1.D_TA	By Sex: Male	229	687
C2.1.D_TA	Sum of Sex disaggregates	8,647	9,656
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,540	9,656
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	82	81
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	143	606
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	83	82
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,232	8,887
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	8,540	9,656
CARE_NEW_DSD	Number of HIV-infected adults and children	5,946	6,981



	newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	82	81
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	143	606
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	83	82
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,638	6,212
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	5,946	6,981
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	97	111
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	139	139
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	97	111



CARE_SITE	Sum of Numerator Site Support Type disaggregates	97	111
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	139	139
CARE_SITE	Sum of Denominator Site Support Type disaggregates	139	139
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	6,046	12,754
TX_CURR_NGI	Age/Sex: <1 Male	139	212
TX_CURR_NGI	Age/Sex: 1-4 Male	90	94
TX_CURR_NGI	Age/Sex: 5-14 Male	23	23
TX_CURR_NGI	Age/Sex: 15+ Male	515	1,054
TX_CURR_NGI	Age/Sex: <1 Female	145	218
TX_CURR_NGI	Age/Sex: 1-4 Female	93	97
TX_CURR_NGI	Age/Sex: 5-14 Female	29	30
TX_CURR_NGI	Age/Sex: 15+ Female	5,012	11,026
TX_CURR_NGI	Sum of Age/Sex disaggregates	6,046	12,754
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	139	212
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	145	218
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	113	117
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	515	1,054
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	122	127
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	5,012	11,026
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	5,762	12,324
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	235	244
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	5,527	12,080
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,046	12,754



TX_CURR_TA	Age/Sex: <1 Male	139	212
TX_CURR_TA	Age/Sex: 1-4 Male	90	94
TX_CURR_TA	Age/Sex: 5-14 Male	23	23
TX_CURR_TA	Age/Sex: 15+ Male	515	1,054
TX_CURR_TA	Age/Sex: <1 Female	145	218
TX_CURR_TA	Age/Sex: 1-4 Female	93	97
TX_CURR_TA	Age/Sex: 5-14 Female	29	30
TX_CURR_TA	Age/Sex: 15+ Female	5,012	11,026
TX_CURR_TA	Sum of Age/Sex disaggregations	519	674
TX_CURR_TA	Aggregated Age/Sex: <1 Male	139	212
TX_CURR_TA	Aggregated Age/Sex: <1 Female	145	218
TX_CURR_TA	Aggregated Age/Sex: <15 Male	113	117
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	515	1,054
TX_CURR_TA	Aggregated Age/Sex: <15 Female	122	127
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,012	11,026
TX_CURR_TA	Sum of Aggregated Age/Sex <15	235	244
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,527	12,080
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,762	12,324
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,194	7,385
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	82	80
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	3	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	143	606
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	83	80
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,044	6,776
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,194	7,385
TX_NEW_DSD	Pregnancy status	2,044	6,776
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after	873	2,052



	initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,027	2,359
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	121
TX_SITE	Total number of PEPFAR-supported ART sites	8	139
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	7	121
TX_SITE	Sum of Numerator Site Support Type disaggregates	7	121
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	8	139
TX_SITE	Sum of Denominator Site Support Type disaggregates	8	139
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	144	144
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV	144	144



	service delivery points: PMTCT, Care and Treatment		
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	144	144
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	144	144
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	144	144
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	144	144
FPINT_SITE_DSD	Service delivery type: Community	0	0
FPINT_SITE_DSD	Service delivery type: Clinical	144	144
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	144	144
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	163	163
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163



QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	163	163
QI_SITE	Sum of Numerator Site Support Type disaggregates	163	163
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	163	163
QI_SITE	Sum of Denominator Site Support Type disaggregates	163	163

Implementing Mechanism Details

Mechanism ID: 13630	Mechanism Name: PSI-CPP (Combination Prevention Program)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Mobile Population
- Safe Motherhood
- Workplace Programs
- End-of-Program Evaluation

Budget Code Information

Mechanism ID:	13630		
Mechanism Name:	PSI-CPP (Combination Prevention Program)		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	19	
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	195	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,000	
VMMC_CIRC_DSD	By Age: <1	2,000	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	6,900	
VMMC_CIRC_DSD	By Age: 15-19	1,800	
VMMC_CIRC_DSD	By Age: 20-24	800	
VMMC_CIRC_DSD	By Age: 25-49	500	
VMMC_CIRC_DSD	By Age: 50+	0	
VMMC_CIRC_DSD	Sum of age disaggregates	12,000	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	40	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,000	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	2,960	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	10,000	
VMMC_CIRC_DSD	By circumcision technique: Device-based	2,000	



	VMMC		
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	9,800	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	200	
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,000	
VMMC_CIRC_NGI	By Age: <1	2,000	
VMMC_CIRC_NGI	By Age: 1-9	0	
VMMC_CIRC_NGI	By Age: 10-14	6,900	
VMMC_CIRC_NGI	By Age: 15-19	1,800	
VMMC_CIRC_NGI	By Age: 20-24	800	
VMMC_CIRC_NGI	By Age: 25-49	500	
VMMC_CIRC_NGI	By Age: 50+	0	
VMMC_CIRC_NGI	Sum of Age disaggregates	12,000	
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	40	
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,000	
VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	2,960	
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	10,000	
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	2,000	
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of	9,800	

	circumcision surgery		
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	200	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	53,285	
PP_PREV_DSD	Total number of people in the target population	324,484	
PP_PREV_DSD	Age/sex: 10-14 Male	7,060	
PP_PREV_DSD	Age/sex: 15-19 Male	12,500	
PP_PREV_DSD	Age/sex: 20-24 Male	5,590	
PP_PREV_DSD	Age/sex: 25-49 Male	2,790	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	6,330	
PP_PREV_DSD	Age/sex: 15-19 Female	11,410	
PP_PREV_DSD	Age/sex: 20-24 Female	5,070	
PP_PREV_DSD	Age/sex: 25-49 Female	2,535	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	53,285	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	600	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	400	
KP_PREV_DSD	By key population type: Men who have sex	200	



	with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
--	--	--	--

Implementing Mechanism Details

Mechanism ID: 13357	Mechanism Name: HealthQual
Funding Agency: HHS/HRSA	Procurement Type: Contract
Prime Partner Name: New York AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 25,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	25,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	13357		
Mechanism Name:	HealthQual		
Prime Partner Name:	New York AIDS Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	25,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13144	Mechanism Name: URC-Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 382,634	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Medical Research Council	National Emergency Response Council on HIV and AIDS	National Health Laboratory Services
--------------------------	---	-------------------------------------



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs

Budget Code Information

Mechanism ID: 13144			
Mechanism Name: URC-Lab			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery	29	29	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	17	20	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	29	29	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	103	10	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	13	13	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	10	12	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	29	29	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	17	20	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	29	29	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	103	105	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	18		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	15		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	18		Redacted

LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	46	49	Redacted
LAB_CAP_DSD	By clinical laboratories	29	29	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	15	17	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	29	29	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	17	20	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	46	49	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	92	100	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	130	150	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	120	130	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	110	130	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	35	36	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	25	25	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	1	Redacted



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	20	20	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	20	20	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	18	18	Redacted

Implementing Mechanism Details

Mechanism ID: 11673	Mechanism Name: DoD/USDF Umbutfo Swaziland Defence Force
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 750,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	750,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	150,000
Food and Nutrition: Commodities	30,000

Key Issues

Child Survival Activities
Military Population
Safe Motherhood
TB
Workplace Programs
Family Planning



Budget Code Information

Mechanism ID: 11673			
Mechanism Name: DoD/USDF Umbutfo Swaziland Defence Force			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	130,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	73,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	437,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	1	1
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	9	9
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family	1	1



	Planning & Integration Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1	1
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	20	22
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20	22
PMTCT_ARV_DSD	Life-long ART (including Option B+)	20	22
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5	7
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	15
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	20	22
PMTCT_ARV_DSD	Sum of New and Current disaggregates	20	22
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	20	22
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	20	22
PMTCT_ARV_NGI	Life-long ART (including Option B+)	20	22
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5	7
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	15
PMTCT_ARV_NGI	Sum of Regimen disaggregates	20	22
PMTCT_ARV_NGI	Sum of New and Current disaggregates	20	22



PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1	1
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1	1
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0
PMTCT_SITE	Sum of Numerator Support Type disaggregates	1	1
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20	22
PMTCT_STAT_DSD	Number of new ANC and L&D clients	20	22
PMTCT_STAT_DSD	By: Known positives at entry	17	18
PMTCT_STAT_DSD	By: Number of new positives identified	3	4
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	20	22
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20	22
PMTCT_STAT_NGI	Number of new ANC and L&D clients	20	22
PMTCT_STAT_NGI	By: Known positives at entry	17	18
PMTCT_STAT_NGI	By: Number of new positives identified	3	4
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	20	22
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	300	300



VMMC_CIRC_DSD	By Age: 15-19	120	120
VMMC_CIRC_DSD	By Age: 20-24	90	90
VMMC_CIRC_DSD	By Age: 25-49	90	90
VMMC_CIRC_DSD	Sum of age disaggregates	300	300
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	93	93
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	201	201
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6	6
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	60	60
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	240	240
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	300	300
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	300	300
VMMC_CIRC_NGI	By Age: 15-19	120	120
VMMC_CIRC_NGI	By Age: 20-24	90	90
VMMC_CIRC_NGI	By Age: 25-49	90	90
VMMC_CIRC_NGI	Sum of Age disaggregates	300	300
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	93	93
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	201	201



VMMC_CIRC_NGI	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6	6
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	60	60
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	240	240
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	300	300
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,500	8,500
PP_PREV_DSD	Total number of people in the target population	32,000	32,000
PP_PREV_DSD	Age/sex: 10-14 Male	940	940
PP_PREV_DSD	Age/sex: 15-19 Male	1,225	1,225
PP_PREV_DSD	Age/sex: 20-24 Male	795	795
PP_PREV_DSD	Age/sex: 25-49 Male	563	563
PP_PREV_DSD	Age/sex: 50+ Male	216	216
PP_PREV_DSD	Age/sex: 10-14 Female	1,141	1,141
PP_PREV_DSD	Age/sex: 15-19 Female	1,392	1,392
PP_PREV_DSD	Age/sex: 20-24 Female	870	870
PP_PREV_DSD	Age/sex: 25-49 Female	975	975
PP_PREV_DSD	Age/sex: 50+ Female	383	383
PP_PREV_DSD	Sum of Age/Sex disaggregates	8,500	8,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,000	2,000



HTC_TST_DSD	By Test Result: Negative	1,400	1,400
HTC_TST_DSD	By Test Result: Positive	600	600
HTC_TST_DSD	Sum of Test Result disaggregates	2,000	2,000
HTC_TST_DSD	Age/sex: <1 Male	26	26
HTC_TST_DSD	Age/sex: 1-4 Male	81	81
HTC_TST_DSD	Age/sex: 5-9 Male	29	29
HTC_TST_DSD	Age/sex: 10-14 Male	16	16
HTC_TST_DSD	Age/sex: 15-19 Male	39	39
HTC_TST_DSD	Age/sex: 20-24 Male	107	107
HTC_TST_DSD	Age/sex: 25-49 Male	319	319
HTC_TST_DSD	Age/sex: 50+ Male	100	100
HTC_TST_DSD	Age/sex: <1 Female	20	20
HTC_TST_DSD	Age/sex: 1-4 Female	63	63
HTC_TST_DSD	Age/sex: 5-9 Female	22	22
HTC_TST_DSD	Age/sex: 10-14 Female	16	16
HTC_TST_DSD	Age/sex: 15-19 Female	170	170
HTC_TST_DSD	Age/sex: 20-24 Female	330	330
HTC_TST_DSD	Age/sex: 25-49 Female	531	531
HTC_TST_DSD	Age/sex: 50+ Female	130	130
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,999	1,999
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	152	152
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	565	565
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	121	121
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,162	1,162
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	273	273
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,727	1,727
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,000	2,000
HTC_TST_NGI	Number of individuals who received T&C	2,000	2,000



	services for HIV and received their test results during the past 12 months		
HTC_TST_NGI	By Test Result: Negative	1,400	1,400
HTC_TST_NGI	By Test Result: Positive	600	600
HTC_TST_NGI	Sum of Test Result disaggregates	2,000	2,000
HTC_TST_NGI	Age/sex: <1 Male	21	21
HTC_TST_NGI	Age/sex: 1-4 Male	67	67
HTC_TST_NGI	Age/sex: 5-9 Male	24	24
HTC_TST_NGI	Age/sex: 10-14 Male	13	13
HTC_TST_NGI	Age/sex: 15-19 Male	32	32
HTC_TST_NGI	Age/sex: 20-24 Male	88	88
HTC_TST_NGI	Age/sex: 25-49 Male	261	261
HTC_TST_NGI	Age/sex: 50+ Male	82	82
HTC_TST_NGI	Age/sex: <1 Female	22	22
HTC_TST_NGI	Age/sex: 1-4 Female	69	69
HTC_TST_NGI	Age/sex: 5-9 Female	24	24
HTC_TST_NGI	Age/sex: 10-14 Female	18	18
HTC_TST_NGI	Age/sex: 15-19 Female	187	187
HTC_TST_NGI	Age/sex: 20-24 Female	364	364
HTC_TST_NGI	Age/sex: 25-49 Female	585	585
HTC_TST_NGI	Age/sex: 50+ Female	143	143
HTC_TST_NGI	Sum of Age/Sex disaggregates	2,000	2,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	125	125
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	463	463
HTC_TST_NGI	Aggregated Age/sex: <15 Female	133	133
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,279	1,279
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	258	258
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,742	1,742
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	2,000	2,000
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	3,000	3,000



GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	210	210
GEND_NORM_DSD	By Age: 15-19	766	766
GEND_NORM_DSD	By Age: 20-24	510	510
GEND_NORM_DSD	By Age: 25+	1,514	1,514
GEND_NORM_DSD	Sum of Age disaggregates	3,000	3,000
GEND_NORM_DSD	By Sex: Male	1,200	1,200
GEND_NORM_DSD	By Sex: Female	1,800	1,800
GEND_NORM_DSD	Sum of Sex disaggregates	3,000	3,000
GEND_NORM_DSD	By type of activity: Individual	0	0
GEND_NORM_DSD	By type of activity: Small Group	2,000	2,000
GEND_NORM_DSD	By type of activity: Community-level	1,000	1,000
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,800	1,800
C2.1.D_DSD	By Age/Sex: <15 Female	82	82
C2.1.D_DSD	By Age/Sex: <15 Male	72	72
C2.1.D_DSD	By Age/Sex: 15+ Female	1,062	1,062
C2.1.D_DSD	By Age/Sex: 15+ Male	584	584
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,800	1,800
C2.1.D_DSD	By Age: <15	154	154
C2.1.D_DSD	By Age: 15+	1,646	1,646
C2.1.D_DSD	Sum of Age disaggregates	1,800	1,800
C2.1.D_DSD	By Sex: Female	1,145	1,145
C2.1.D_DSD	By Sex: Male	655	655
C2.1.D_DSD	Sum of Sex disaggregates	1,800	1,800
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,800	1,800
C2.1.D_NGI	By Age/Sex: <15 Female	82	82
C2.1.D_NGI	By Age/Sex: <15 Male	72	72
C2.1.D_NGI	By Age/Sex: 15+ Female	1,062	1,062
C2.1.D_NGI	By Age/Sex: 15+ Male	584	584
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,800	1,800



C2.1.D_NGI	By Age: <15	154	154
C2.1.D_NGI	By Age: 15+	1,646	1,646
C2.1.D_NGI	Sum of Age disaggregates	1,800	1,800
C2.1.D_NGI	By Sex: Female	1,145	1,145
C2.1.D_NGI	By Sex: Male	655	655
C2.1.D_NGI	Sum of Sex disaggregates	1,800	1,800
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,800	1,800
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,800	1,800
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,800	1,800
CARE_CURR_DSD	Age/sex: <1 Male	16	16
CARE_CURR_DSD	Age/sex: 1-4 Male	23	23
CARE_CURR_DSD	Age/sex: 5-9 Male	16	16
CARE_CURR_DSD	Age/sex: 10-14 Male	13	13
CARE_CURR_DSD	Age/sex: 15-19 Male	6	6
CARE_CURR_DSD	Age/sex: 20-24 Male	29	29
CARE_CURR_DSD	Age/sex: 25-49 Male	478	478
CARE_CURR_DSD	Age/sex: 50+ Male	95	95
CARE_CURR_DSD	Age/sex: <1 Female	19	19
CARE_CURR_DSD	Age/sex: 1-4 Female	25	25
CARE_CURR_DSD	Age/sex: 5-9 Female	17	17
CARE_CURR_DSD	Age/sex: 10-14 Female	17	17
CARE_CURR_DSD	Age/sex: 15-19 Female	38	38
CARE_CURR_DSD	Age/sex: 20-24 Female	157	157
CARE_CURR_DSD	Age/sex: 25-49 Female	747	747
CARE_CURR_DSD	Age/sex: 50+ Female	104	104
CARE_CURR_DSD	Sun of Age/Sex disaggregates	1,800	1,800



CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	67	67
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	607	607
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	79	79
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,047	1,047
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,800	1,800
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	600	600
CARE_NEW_DSD	Age/sex: <1 Male	6	6
CARE_NEW_DSD	Age/sex: 1-4 Male	10	10
CARE_NEW_DSD	Age/sex: 5-9 Male	7	7
CARE_NEW_DSD	Age/sex: 10-14 Male	6	6
CARE_NEW_DSD	Age/sex: 15-19 Male	3	3
CARE_NEW_DSD	Age/sex: 20-24 Male	11	11
CARE_NEW_DSD	Age/sex: 25-49 Male	177	177
CARE_NEW_DSD	Age/sex: 50+ Male	35	35
CARE_NEW_DSD	Age/sex: <1 Female	6	6
CARE_NEW_DSD	Age/sex: 1-4 Female	10	10
CARE_NEW_DSD	Age/sex: 5-9 Female	6	6
CARE_NEW_DSD	Age/sex: 10-14 Female	6	6
CARE_NEW_DSD	Age/sex: 15-19 Female	12	12
CARE_NEW_DSD	Age/sex: 20-24 Female	47	47
CARE_NEW_DSD	Age/sex: 25-49 Female	225	225
CARE_NEW_DSD	Age/sex: 50+ Female	33	33
CARE_NEW_DSD	Sum of Age/sex disaggregates	600	600
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	10	10



CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	81	81
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	9	9
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	500	500
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	600	600
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	9	9
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	9	9
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	0	0
CARE_SITE	Sum of Numerator Site Support Type disaggregates	9	9
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	9	9
CARE_SITE	By site support type: Technical	0	0



	Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services		
CARE_SITE	Sum of Denominator Site Support Type disaggregates	9	9
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	9	9
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	9	9
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	54	54
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	54	54
FN_THER_DSD	Age: 5-14	27	27
FN_THER_DSD	Age: 15-17	27	27
FN_THER_DSD	Sum of Age disaggregates	54	54
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	280	280
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	280	280
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	1	1
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	1	1
TX_CURR_DSD	Number of adults and children receiving	1,380	1,380



	antiretroviral therapy (ART)		
TX_CURR_DSD	Age/Sex: <1 Male	13	13
TX_CURR_DSD	Age/Sex: 1-4 Male	19	19
TX_CURR_DSD	Age/Sex: 5-14 Male	24	24
TX_CURR_DSD	Age/Sex: 15+ Male	459	459
TX_CURR_DSD	Age/Sex: <1 Female	16	16
TX_CURR_DSD	Age/Sex: 1-4 Female	20	20
TX_CURR_DSD	Age/Sex: 5-14 Female	28	28
TX_CURR_DSD	Age/Sex: 15+ Female	801	801
TX_CURR_DSD	Sum of age/sex disaggregates	120	120
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	9
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	63
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	13	13
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	16	16
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	55	55
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	459	459
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	66	66
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	800	800
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	121	121
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,259	1,259
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,380	1,380
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,380	1,380
TX_CURR_NGI	Age/Sex: <1 Male	13	13
TX_CURR_NGI	Age/Sex: 1-4 Male	19	19
TX_CURR_NGI	Age/Sex: 5-14 Male	24	24
TX_CURR_NGI	Age/Sex: 15+ Male	459	459
TX_CURR_NGI	Age/Sex: <1 Female	16	16



TX_CURR_NGI	Age/Sex: 1-4 Female	21	21
TX_CURR_NGI	Age/Sex: 5-14 Female	28	28
TX_CURR_NGI	Age/Sex: 15+ Female	800	800
TX_CURR_NGI	Sum of Age/Sex disaggregates	1,380	1,380
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	14	14
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	19	19
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	59	59
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	455	455
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	72	72
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	794	794
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,380	1,380
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	131	131
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,249	1,249
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	300	300
TX_NEW_DSD	By Age/Sex: <1 Male	3	3
TX_NEW_DSD	By Age/Sex: 1-4 Male	4	4
TX_NEW_DSD	By Age/Sex: 5-9 Male	4	4
TX_NEW_DSD	By Age/Sex: 10-14 Male	3	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	1	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	6	6
TX_NEW_DSD	By Age/Sex: 25-49 Male	85	85
TX_NEW_DSD	By Age/Sex: 50+ Male	17	17
TX_NEW_DSD	By Age/Sex: <1 Female	4	4
TX_NEW_DSD	By Age/Sex: 1-4 Female	5	5
TX_NEW_DSD	By Age/Sex: 5-9 Female	4	4
TX_NEW_DSD	By Age/Sex: 10-14 Female	4	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	6	6
TX_NEW_DSD	By Age/Sex: 20-24 Female	24	24
TX_NEW_DSD	By Age/Sex: 25-49 Female	114	114
TX_NEW_DSD	By Age/Sex: 50+ Female	16	16
TX_NEW_DSD	Sum of Age/Sex disaggregates	300	300



TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	29	29
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	130	130
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	14	14
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	126	126
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	299	299
TX_NEW_DSD	Pregnancy status	52	52
TX_NEW_DSD	Breastfeeding status	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,325	11,325
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,380	1,380
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	75	75
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57	57
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,193	1,193
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78	78



TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59	59
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,243	1,234
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	293	293
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,032	1,032
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	298	298
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,082	1,082
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107	107
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and	143	143

	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	9	9
TX_SITE	Total number of PEPFAR-supported ART sites	9	9
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	6	6
LAB_CAP_DSD	By clinical laboratories	1	1
LAB_CAP_DSD	By Point-of-care testing sites	5	5
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	6	6
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	6
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	7	3
HRH_PRE	By Graduates: Nurses	1	
HRH_PRE	By Graduates: Midwives	1	
HRH_PRE	By Graduates: Laboratory professionals	4	
HRH_PRE	By Graduates: Other	1	2
HRH_PRE	Sum of Graduates disaggreagtes	7	3
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	5
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and	9	9



	Treatment		
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3	5
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	3	5
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	9	9
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	9	9
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	6	6
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	9	9
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.	30	30
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	36	36
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,800	1,800



TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,800	1,800
TB_SCREEN_DSD	Age: <1	35	35
TB_SCREEN_DSD	Age: 1-4	48	48
TB_SCREEN_DSD	Age: 5-9	33	33
TB_SCREEN_DSD	Age: 10-14	30	30
TB_SCREEN_DSD	Age: 15-19	43	43
TB_SCREEN_DSD	Age: 20-24	183	183
TB_SCREEN_DSD	Age: 25-49	1,227	1,227
TB_SCREEN_DSD	Age: 50+	201	201
TB_SCREEN_DSD	Sum of Age disaggregates	189	189
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	146	146
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	1,654	1,654
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	1,800	1,800
TB_SCREEN_DSD	Sex: Male	674	674
TB_SCREEN_DSD	Sex: Female	1,126	1,126
TB_SCREEN_DSD	Sum of Sex disaggregates	1,800	1,800

Implementing Mechanism Details

Mechanism ID: 10703	Mechanism Name: MSH-SIAPS (Systems for Improved Access to Pharmaceuticals and Services Program)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 1,181,134	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 218,866	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,181,134

Sub Partner Name(s)

Luvit Solutions		
-----------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
----------------------------	---------

Key Issues

- Malaria (PMI)
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	10703		
Mechanism Name:	MSH-SIAPS (Systems for Improved Access to Pharmaceuticals and Services Program)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	140,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	461,134	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	147	153
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	1
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	134	134
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and	134	134



	Support Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	145	145
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	82	82
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family	0	0



	Planning & Integration Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	151	151
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	4	4
TX_DIST	Total number of PEPFAR supported District Health Offices	4	4
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	130	150
LAB_CAP_DSD	By clinical laboratories	14	14
LAB_CAP_DSD	By Point-of-care testing sites	116	116
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	130	150
LAB_CAP_DSD	Sum of Site Support Type disaggregates	130	150
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	20	22
HRH_PRE	By Graduates: Other	20	22
HRH_PRE	Sum of Graduates disaggreagtes	20	22
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity	123	140



	completed that addresses clinical HIV programs and has documented process results in the last 6 months		
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	144	150
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	123	140
QI_SITE	Sum of Numerator Site Support Type disaggregates	123	140
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	0	0
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	144	150
QI_SITE	Sum of Denominator Site Support Type disaggregates	144	150
SC_STOCK	Number of stock status observations for one or more tracer commodities that are between	4,152	1,650



	the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.		
SC_STOCK	Total number of stock status observations for one or more tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system	6,920	1,736
SC_STOCK	System Level: Central Medical Stores	8	24
SC_STOCK	System Level: Regional Medical Stores	0	0
SC_STOCK	System Level: District	0	0
SC_STOCK	System Level: Health facility	1,728	684
SC_STOCK	Commodity: Condoms	1,728	12
SC_STOCK	Commodity: ARV drugs	1,728	504
SC_STOCK	Commodity: Rapid test kits	1,728	192
SC_STOCK	Commodity: OI drugs	1,728	504
SC_STOCK	Commodity: Other	1,728	12

Implementing Mechanism Details

Mechanism ID: 10247	Mechanism Name: ICAP/CDC: Improving Quality of Treatment Services
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 897,724	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

Baylor University	Cabrini Ministries	Nazarene Compassionate Ministries
NERCHA	World Vision International	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Child Survival Activities
- Military Population
- TB
- Workplace Programs
- End-of-Program Evaluation
- Family Planning

Budget Code Information

Mechanism ID:	10247		
Mechanism Name:	ICAP/CDC: Improving Quality of Treatment Services		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	112	112	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	52	52	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	60	60	Redacted
SITE_SUPP	By program area/support type: Care	52	52	Redacted



	and Support Direct Service Delivery (DSD)			
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	60	60	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	52	52	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	60	60	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	50	50	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	54	54	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	64,660		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,966		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,572		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	38,155		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	20,967		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	64,660		Redacted
C2.1.D_DSD	By Age: <15	5,538		Redacted
C2.1.D_DSD	By Age: 15+	59,122		Redacted
C2.1.D_DSD	Sum of Age disaggregates	64,660		Redacted
C2.1.D_DSD	By Sex: Female	41,121		Redacted
C2.1.D_DSD	By Sex: Male	23,539		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	64,660		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	83,240		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	3,818		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	3,311		Redacted



C2.1.D_NGI	By Age/Sex: 15+ Female	49,119		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	26,992		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	83,240		Redacted
C2.1.D_NGI	By Age: <15	7,129		Redacted
C2.1.D_NGI	By Age: 15+	76,111		Redacted
C2.1.D_NGI	Sum of Age disaggregates	83,240		Redacted
C2.1.D_NGI	By Sex: Female	52,937		Redacted
C2.1.D_NGI	By Sex: Male	30,303		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	83,240		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	18,580		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	852		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	739		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	10,964		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	6,025		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	18,580		Redacted
C2.1.D_TA	By Age: <15	1,591		Redacted
C2.1.D_TA	By Age: 15+	16,989		Redacted
C2.1.D_TA	Sum of Age disaggregates	18,580		Redacted
C2.1.D_TA	By Sex: Female	11,816		Redacted
C2.1.D_TA	By Sex: Male	6,764		Redacted
C2.1.D_TA	Sum of Sex disaggregates	18,580		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	61,500		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	64,660		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	69,934	76,429	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	656	709	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	945	1,022	Redacted



TX_CURR_DSD	Age/Sex: 5-14 Male	1,202	1,300	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	23,240	25,583	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	819	882	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,070	1,153	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,434	1,545	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	40,568	44,235	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	6,126	6,611	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	9	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	63	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	656	709	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	819	882	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,803	3,031	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,240	25,583	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,323	3,580	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,568	44,235	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,126	6,611	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	63,808	69,818	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	69,934	76,429	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	76,126	84,122	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	796	859	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	1,019	1,111	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,296	1,413	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	25,287	28,176	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	1,069	1,154	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	1,171	1,279	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,569	1,713	Redacted



TX_CURR_NGI	Age/Sex: 15+ Female	43,919	48,417	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	76,126	84,122	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	796	859	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	1,069	1,154	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	3,111	3,383	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	25,287	28,176	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	3,809	4,146	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	43,919	48,417	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	76,126	84,122	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	6,920	7,529	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	69,206	76,593	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,192	7,693	Redacted
TX_CURR_TA	Age/Sex: <1 Male	140	150	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	74	89	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	94	113	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	2,047	2,593	Redacted
TX_CURR_TA	Age/Sex: <1 Female	250	272	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	101	126	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	135	168	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	3,351	4,182	Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	794	918	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	140	150	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	250	272	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	308	352	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,047	2,593	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	486	566	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,351	4,182	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	794	918	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,398	6,775	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex	6,192	7,693	Redacted



	disaggregates			
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,401	12,401	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	126	126	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	181	181	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	130	130	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	100	100	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	43	43	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	212	212	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,517	3,517	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	698	698	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	171	171	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	224	224	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	148	148	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	152	152	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	242	242	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,003	1,003	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,784	4,784	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	670	670	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,401	12,401	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	109	109	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	537	537	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,470	4,470	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	139	139	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	695	695	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,699	6,699	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,401	12,401	Redacted



TX_NEW_DSD	Pregnancy status	1,169	1,169	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,438	9,348	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,699	10,507	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	478	528	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	361	400	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,599	8,420	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	549	595	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	415	449	Redacted

TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,735	9,463	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,865	739	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,573	8,609	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,096	832	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,603	9,675	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	684	743	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults)	912	990	Redacted



	and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	104	104	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	112	112	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	50	50	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	54	54	Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	104	104	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	50	50	Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	62	62	Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type	112	112	Redacted



	disaggregates			
FPINT_SITE_DSD	Service delivery type: Community	0	0	Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	112	112	Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	112	112	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	112	112	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	112	112	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	52	52	Redacted
QI_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	60	60	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	112	112	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV	52	52	Redacted



	Treatment, TB care, PMTCT, VMMC, HTC			
QI_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	60	60	Redacted
QI_SITE	Sum of Denominator Site Support Type disaggregates	112	112	Redacted

Implementing Mechanism Details

Mechanism ID: 10157	Mechanism Name: PACT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 1,156,997	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 263,811	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,156,997

Sub Partner Name(s)

Bantwana Initiative	Cabrini Ministries Swaziland	Cheshire Homes
Khulisa	Salvation Army Swaziland	Save the Children Swaziland (SCSWD)
Super Buddies	Swaziland Action Group Against Abuse	Swaziland Business Coalition Against HIV/AIDS
Swaziland National Network of	TechnoServe	



People Living with HIV/AIDS		
-----------------------------	--	--

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	6,313
Economic Strengthening	5,495
Education	2,196
Food and Nutrition: Policy, Tools, and Service Delivery	1,830
Gender: Gender Equality	10,768
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

TB

Budget Code Information

Mechanism ID: 10157			
Mechanism Name: PACT			
Prime Partner Name: Pact, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	616,998	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	29,999	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	35,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	20	20
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	11	11
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	29	29
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	11	11
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	138	138
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	240	240



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,686	6,562
PP_PREV_DSD	Total number of people in the target population	102,156	102,156
PP_PREV_DSD	Age/sex: 10-14 Male	2,174	725
PP_PREV_DSD	Age/sex: 15-19 Male	2,837	946
PP_PREV_DSD	Age/sex: 20-24 Male	1,839	613
PP_PREV_DSD	Age/sex: 25-49 Male	1,306	435
PP_PREV_DSD	Age/sex: 50+ Male	502	167
PP_PREV_DSD	Age/sex: 10-14 Female	2,642	881
PP_PREV_DSD	Age/sex: 15-19 Female	3,226	1,075
PP_PREV_DSD	Age/sex: 20-24 Female	2,014	671
PP_PREV_DSD	Age/sex: 25-49 Female	2,258	753
PP_PREV_DSD	Age/sex: 50+ Female	888	296
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,686	6,562
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,623	1,156
HTC_TST_DSD	By Test Result: Negative	4,137	1,034
HTC_TST_DSD	By Test Result: Positive	486	122
HTC_TST_DSD	Sum of Test Result disaggregates	4,623	1,156
HTC_TST_DSD	Age/sex: <1 Male	0	0
HTC_TST_DSD	Age/sex: 1-4 Male	52	13
HTC_TST_DSD	Age/sex: 5-9 Male	139	35
HTC_TST_DSD	Age/sex: 10-14 Male	165	41
HTC_TST_DSD	Age/sex: 15-19 Male	135	34
HTC_TST_DSD	Age/sex: 20-24 Male	143	36
HTC_TST_DSD	Age/sex: 25-49 Male	832	207
HTC_TST_DSD	Age/sex: 50+ Male	514	128
HTC_TST_DSD	Age/sex: <1 Female	0	0
HTC_TST_DSD	Age/sex: 1-4 Female	102	26



HTC_TST_DSD	Age/sex: 5-9 Female	169	42
HTC_TST_DSD	Age/sex: 10-14 Female	142	36
HTC_TST_DSD	Age/sex: 15-19 Female	189	47
HTC_TST_DSD	Age/sex: 20-24 Female	214	54
HTC_TST_DSD	Age/sex: 25-49 Female	1,380	345
HTC_TST_DSD	Age/sex: 50+ Female	447	112
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,623	1,156
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	356	89
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,624	406
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	413	103
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,230	558
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	769	192
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,854	964
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,623	1,156
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,623	1,156
HTC_TST_NGI	By Test Result: Negative	4,137	1,034
HTC_TST_NGI	By Test Result: Positive	486	122
HTC_TST_NGI	Sum of Test Result disaggregates	4,623	1,156
HTC_TST_NGI	Age/sex: <1 Male	0	0
HTC_TST_NGI	Age/sex: 1-4 Male	52	13
HTC_TST_NGI	Age/sex: 5-9 Male	139	35
HTC_TST_NGI	Age/sex: 10-14 Male	165	41
HTC_TST_NGI	Age/sex: 15-19 Male	135	34
HTC_TST_NGI	Age/sex: 20-24 Male	143	36
HTC_TST_NGI	Age/sex: 25-49 Male	832	207
HTC_TST_NGI	Age/sex: 50+ Male	514	128
HTC_TST_NGI	Age/sex: <1 Female	0	0



HTC_TST_NGI	Age/sex: 1-4 Female	102	26
HTC_TST_NGI	Age/sex: 5-9 Female	169	42
HTC_TST_NGI	Age/sex: 10-14 Female	142	36
HTC_TST_NGI	Age/sex: 15-19 Female	189	47
HTC_TST_NGI	Age/sex: 20-24 Female	214	54
HTC_TST_NGI	Age/sex: 25-49 Female	1,380	345
HTC_TST_NGI	Age/sex: 50+ Female	447	112
HTC_TST_NGI	Sum of Age/Sex disaggregates	4,623	1,156
HTC_TST_NGI	Aggregated Age/sex: <15 Male	356	89
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,624	406
HTC_TST_NGI	Aggregated Age/sex: <15 Female	413	103
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	2,230	558
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	769	192
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	3,854	964
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,623	1,156
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	3,825	1,275
GEND_NORM_DSD	By Age: 0-9	0	0
GEND_NORM_DSD	By Age: 10-14	268	89
GEND_NORM_DSD	By Age: 15-19	977	326
GEND_NORM_DSD	By Age: 20-24	650	217
GEND_NORM_DSD	By Age: 25+	1,930	643
GEND_NORM_DSD	Sum of Age disaggregates	3,825	1,275
GEND_NORM_DSD	By Sex: Male	1,441	480
GEND_NORM_DSD	By Sex: Female	2,384	795
GEND_NORM_DSD	Sum of Sex disaggregates	3,825	1,275
GEND_NORM_DSD	By type of activity: Individual	1,763	588
GEND_NORM_DSD	By type of activity: Small Group	2,062	688
GEND_NORM_DSD	By type of activity: Community-level	0	0
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to	721	180



	access HIV services		
OVC_ACC_DSD	Sex: Male	372	93
OVC_ACC_DSD	Sex: Female	349	87
OVC_ACC_DSD	Sum of Sex disaggregates	721	180
OVC_ACC_DSD	Age: <1	0	0
OVC_ACC_DSD	Age: 1-4	0	0
OVC_ACC_DSD	Age: 5-9	31	8
OVC_ACC_DSD	Age: 10-14	136	34
OVC_ACC_DSD	Age: 15-17	334	83
OVC_ACC_DSD	Age: 18+	220	55
OVC_ACC_DSD	Sum of Age disaggregates	721	180
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,639	9,410
OVC_SERV_DSD	Sex: Male	18,393	4,598
OVC_SERV_DSD	Sex: Female	19,246	4,812
OVC_SERV_DSD	Sum of Sex disaggregates	37,639	9,410
OVC_SERV_DSD	Age: <1	136	34
OVC_SERV_DSD	Age: 1-4	2,994	749
OVC_SERV_DSD	Age: 5-9	4,578	1,145
OVC_SERV_DSD	Age: 10-14	13,179	3,294
OVC_SERV_DSD	Age: 15-17	11,578	2,894
OVC_SERV_DSD	Age: 18+	5,174	1,294
OVC_SERV_DSD	Sum of Age disaggregates	37,639	9,410
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,855	2,964
C2.1.D_DSD	By Age/Sex: <15 Female	1,287	322
C2.1.D_DSD	By Age/Sex: <15 Male	1,232	308
C2.1.D_DSD	By Age/Sex: 15+ Female	6,134	1,534
C2.1.D_DSD	By Age/Sex: 15+ Male	3,202	800
C2.1.D_DSD	Sum of Age/Sex disaggregates	11,855	2,964
C2.1.D_DSD	By Age: <15	2,519	630



C2.1.D_DSD	By Age: 15+	9,336	2,334
C2.1.D_DSD	Sum of Age disaggregates	11,855	2,964
C2.1.D_DSD	By Sex: Female	7,421	1,855
C2.1.D_DSD	By Sex: Male	4,434	1,109
C2.1.D_DSD	Sum of Sex disaggregates	11,855	2,964
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	11,855	2,964
C2.1.D_NGI	By Age/Sex: <15 Female	1,287	322
C2.1.D_NGI	By Age/Sex: <15 Male	1,232	308
C2.1.D_NGI	By Age/Sex: 15+ Female	6,134	1,534
C2.1.D_NGI	By Age/Sex: 15+ Male	3,202	800
C2.1.D_NGI	Sum of Age/Sex disaggregates	11,855	2,964
C2.1.D_NGI	By Age: <15	2,519	630
C2.1.D_NGI	By Age: 15+	9,336	2,334
C2.1.D_NGI	Sum of Age disaggregates	11,855	2,964
C2.1.D_NGI	By Sex: Female	7,421	1,855
C2.1.D_NGI	By Sex: Male	4,434	1,109
C2.1.D_NGI	Sum of Sex disaggregates	11,855	2,964
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	9,168	2,292
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	11,855	2,964
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,840	2,460
CARE_CURR_DSD	Age/sex: <1 Male	0	0
CARE_CURR_DSD	Age/sex: 1-4 Male	92	23
CARE_CURR_DSD	Age/sex: 5-9 Male	499	125
CARE_CURR_DSD	Age/sex: 10-14 Male	526	131
CARE_CURR_DSD	Age/sex: 15-19 Male	158	40



CARE_CURR_DSD	Age/sex: 20-24 Male	26	7
CARE_CURR_DSD	Age/sex: 25-49 Male	1,524	381
CARE_CURR_DSD	Age/sex: 50+ Male	775	194
CARE_CURR_DSD	Age/sex: <1 Female	0	0
CARE_CURR_DSD	Age/sex: 1-4 Female	223	56
CARE_CURR_DSD	Age/sex: 5-9 Female	512	127
CARE_CURR_DSD	Age/sex: 10-14 Female	408	102
CARE_CURR_DSD	Age/sex: 15-19 Female	315	79
CARE_CURR_DSD	Age/sex: 20-24 Female	368	92
CARE_CURR_DSD	Age/sex: 25-49 Female	3,363	840
CARE_CURR_DSD	Age/sex: 50+ Female	1,051	263
CARE_CURR_DSD	Sun of Age/Sex disaggregates	9,840	2,460
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,117	279
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,483	621
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,143	286
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,097	1,274
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,840	2,460
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	550	138
CARE_NEW_DSD	Age/sex: <1 Male	0	0
CARE_NEW_DSD	Age/sex: 1-4 Male	5	1
CARE_NEW_DSD	Age/sex: 5-9 Male	28	7
CARE_NEW_DSD	Age/sex: 10-14 Male	30	8
CARE_NEW_DSD	Age/sex: 15-19 Male	9	2
CARE_NEW_DSD	Age/sex: 20-24 Male	2	1



CARE_NEW_DSD	Age/sex: 25-49 Male	85	21
CARE_NEW_DSD	Age/sex: 50+ Male	44	11
CARE_NEW_DSD	Age/sex: <1 Female	0	0
CARE_NEW_DSD	Age/sex: 1-4 Female	13	3
CARE_NEW_DSD	Age/sex: 5-9 Female	28	7
CARE_NEW_DSD	Age/sex: 10-14 Female	22	6
CARE_NEW_DSD	Age/sex: 15-19 Female	17	4
CARE_NEW_DSD	Age/sex: 20-24 Female	20	5
CARE_NEW_DSD	Age/sex: 25-49 Female	189	47
CARE_NEW_DSD	Age/sex: 50+ Female	58	15
CARE_NEW_DSD	Sum of Age/sex disaggregates	550	138
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	63	16
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	140	35
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	63	16
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	284	71
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	550	138
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	11	11
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	11	11
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	11	11
CARE_SITE	By site support type: Technical	0	0



	Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
CARE_SITE	Sum of Numerator Site Support Type disaggregates	11	11
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	11	11
CARE_SITE	Sum of Denominator Site Support Type disaggregates	11	11
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2
FN_SITE	Sum of Numerator Support Type disaggregates	2	2
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2
FN_SITE	Sum of Denominator Support Type disaggregates	2	2
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary	559	140



	food during the reporting period.		
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	559	140
FN_THER_DSD	Age: <1	0	0
FN_THER_DSD	Age: 1-4	18	5
FN_THER_DSD	Age: 5-14	111	27
FN_THER_DSD	Age: 15-17	24	6
FN_THER_DSD	Age: 18+	406	102
FN_THER_DSD	Sum of Age disaggregates	559	140
FN_THER_DSD	Aggregated Age: <18	153	38
FN_THER_DSD	Aggregated Age: 18+	406	102
FN_THER_DSD	Sum of Aggregated Age disaggregates	559	140
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	270	68
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	270	68
TB_ART_DSD	Age: 0-4	0	0
TB_ART_DSD	Age: 5-14	24	6
TB_ART_DSD	Age: 15+	246	62
TB_ART_DSD	Male	137	34
TB_ART_DSD	Female	133	34
TB_ART_DSD	Sum of Sex disaggregates	270	68
TB_ART_DSD	Newly tested	54	14
TB_ART_DSD	Known HIV-positive	216	54
TB_ART_DSD	Sum of Test Status disaggregates	270	68
TB_ART_DSD	Aggregated Age: <15	24	6
TB_ART_DSD	Aggregated Age: 15+	246	62
TB_ART_DSD	Sum of Aggregated Age disaggregates	270	68



TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	2	2
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	2	2
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	2	2
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	2	2
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	2	2
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	333	83
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	333	83
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	333	83
PMTCT_EID_DSD	Sum of Infant Age disaggregates	333	83
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,670	7,670
TX_CURR_DSD	Age/Sex: <1 Male	80	80
TX_CURR_DSD	Age/Sex: 1-4 Male	70	70
TX_CURR_DSD	Age/Sex: 5-14 Male	780	780
TX_CURR_DSD	Age/Sex: 15+ Male	1,889	1,889



TX_CURR_DSD	Age/Sex: <1 Female	99	99
TX_CURR_DSD	Age/Sex: 1-4 Female	170	170
TX_CURR_DSD	Age/Sex: 5-14 Female	700	700
TX_CURR_DSD	Age/Sex: 15+ Female	3,882	3,882
TX_CURR_DSD	Sum of age/sex disaggregates	1,899	1,899
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	25	25
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	63
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	80	80
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	99	99
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	930	930
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,889	1,889
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	969	969
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,882	3,882
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,899	1,899
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,771	5,771
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,670	7,670
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	7,670	7,670
TX_CURR_NGI	Age/Sex: <1 Male	80	80
TX_CURR_NGI	Age/Sex: 1-4 Male	70	70
TX_CURR_NGI	Age/Sex: 5-14 Male	780	780
TX_CURR_NGI	Age/Sex: 15+ Male	1,889	1,889
TX_CURR_NGI	Age/Sex: <1 Female	99	99
TX_CURR_NGI	Age/Sex: 1-4 Female	170	170
TX_CURR_NGI	Age/Sex: 5-14 Female	700	700
TX_CURR_NGI	Age/Sex: 15+ Female	3,882	3,882
TX_CURR_NGI	Sum of Age/Sex disaggregates	7,670	7,670
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	80	80



TX_CURR_NGI	Aggregated Age/Sex: <1 Female	99	99
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	930	930
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	99	99
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	969	969
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,882	3,882
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	5,880	5,880
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,899	1,899
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	3,981	3,981
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,224	306
TX_NEW_DSD	By Age/Sex: <1 Male	17	4
TX_NEW_DSD	By Age/Sex: 1-4 Male	11	3
TX_NEW_DSD	By Age/Sex: 5-9 Male	61	15
TX_NEW_DSD	By Age/Sex: 10-14 Male	63	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	19	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	3	1
TX_NEW_DSD	By Age/Sex: 25-49 Male	184	46
TX_NEW_DSD	By Age/Sex: 50+ Male	94	24
TX_NEW_DSD	By Age/Sex: <1 Female	18	5
TX_NEW_DSD	By Age/Sex: 1-4 Female	27	7
TX_NEW_DSD	By Age/Sex: 5-9 Female	62	16
TX_NEW_DSD	By Age/Sex: 10-14 Female	49	12
TX_NEW_DSD	By Age/Sex: 15-19 Female	38	9
TX_NEW_DSD	By Age/Sex: 20-24 Female	45	11
TX_NEW_DSD	By Age/Sex: 25-49 Female	406	101
TX_NEW_DSD	By Age/Sex: 50+ Female	127	31
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,224	306
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	17	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	152	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	300	75
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	18	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	156	39



	Female		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	616	154
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,224	306
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,125	281
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,253	313
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134	34
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	991	248
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37	9
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	113	28
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the	1,103	276



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134	34
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	99	248
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150	38
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,103	276
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	0
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	0
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	11	11



TX_SITE	Total number of PEPFAR-supported ART sites	11	11
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	11	11
TX_SITE	Sum of Numerator Site Support Type disaggregates	11	11
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	11	11
TX_SITE	Sum of Denominator Site Support Type disaggregates	11	11
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	11	11
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	11	11
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	11	11
QI_SITE	Sum of Numerator Site Support Type disaggregates	11	11
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	11	11



QI_SITE	Sum of Denominator Site Support Type disaggregates	11	11
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	9,840	2,460
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,840	2,460
TB_SCREEN_DSD	Age: <1	0	0
TB_SCREEN_DSD	Age: 1-4	315	79
TB_SCREEN_DSD	Age: 5-9	1,012	253
TB_SCREEN_DSD	Age: 10-14	932	233
TB_SCREEN_DSD	Age: 15-19	473	118
TB_SCREEN_DSD	Age: 20-24	394	98
TB_SCREEN_DSD	Age: 25-49	4,888	1,222
TB_SCREEN_DSD	Age: 50+	1,826	457
TB_SCREEN_DSD	Sum of Age disaggregates	2,732	683
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,259	565
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	7,581	1,895
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	9,840	2,460
TB_SCREEN_DSD	Sex: Male	3,600	900
TB_SCREEN_DSD	Sex: Female	6,240	1,560
TB_SCREEN_DSD	Sum of Sex disaggregates	9,840	2,460



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		0		Redacted	0	761,836
Management Meetings/Professional Development		0		Redacted	0	19,102
Non-ICASS Administrative Costs		0		Redacted	0	127,917
Staff Program Travel		0		Redacted	0	76,409
USG Staff Salaries and Benefits			881,369	Redacted	881,369	497,691
Total	0	0	881,369	0	881,369	1,482,955

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS		GHP-State		Redacted	0	761,836
Management Meetings/Professional Development		GHP-State		Redacted	0	19,102
Non-ICASS		GHP-State	75k=RHAP	Redacted	0	127,917



Administrative Costs			TA; Communication exp=4205; newspapers=1500; 3k=representation			
----------------------	--	--	--	--	--	--

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		10,000		Redacted	10,000	0
ICASS		35,000		Redacted	35,000	0
Management Meetings/Professional Development		5,000		Redacted	5,000	0
Non-ICASS Administrative Costs		6,000		Redacted	6,000	0
Staff Program Travel		15,000		Redacted	15,000	0
USG Staff Salaries and Benefits		64,144		Redacted	64,144	350,000
Total	0	135,144	0	0	135,144	350,000

U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As	Amount	Applied Pipeline
----------	------	----------------	-------------	-------------------	--------	------------------



				Of Last Q1		
Capital Security Cost Sharing		GHP-State		Redacted	10,000	0
ICASS		GHP-State		Redacted	35,000	0
Management Meetings/Professional Development		GHP-State		Redacted	5,000	0
Non-ICASS Administrative Costs		GHP-State		Redacted	6,000	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing	100,000			Redacted	100,000	0
Computers/IT Services		40,000		Redacted	40,000	0
ICASS		400,000		Redacted	400,000	0
Institutional Contractors	285,101			Redacted	285,101	0
Management Meetings/Professional Development	27,000			Redacted	27,000	0
Non-ICASS Administrative Costs		57,744		Redacted	57,744	0



Staff Program Travel		178,000		Redacted	178,000	0
USG Staff Salaries and Benefits	75,399	862,317		Redacted	937,716	0
Total	487,500	1,538,061	0	0	2,025,561	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GAP		Redacted	100,000	0
Computers/IT Services		GHP-State		Redacted	40,000	0
ICASS		GHP-State		Redacted	400,000	0
Management Meetings/Professional Development		GAP		Redacted	27,000	0
Non-ICASS Administrative Costs		GHP-State		Redacted	57,744	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		Redacted	0	19,344



ICASS		115,000		Redacted	115,000	0
Management Meetings/Professional Development		0		Redacted	0	12,000
Non-ICASS Administrative Costs		0		Redacted	0	112,581
Staff Program Travel				Redacted	0	21,500
USG Staff Salaries and Benefits		0		Redacted	0	211,788
Total	0	115,000	0	0	115,000	377,213

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	0	19,344
ICASS		GHP-State		Redacted	115,000	0
Management Meetings/Professional Development		GHP-State		Redacted	0	12,000
Non-ICASS Administrative Costs		GHP-State	cell phone+land line 18k; wireless=8.5k; 6k =fuel; 90k for small grants	Redacted	0	112,581



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		22,300		Redacted	22,300	0
Peace Corps Volunteer Costs		1,013,222		Redacted	1,013,222	0
Total	0	1,035,522	0	0	1,035,522	0

U.S. Peace Corps Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Non-ICASS Administrative Costs		GHP-State		Redacted	22,300	0